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ABSTRACT 
Toll-like receptors (TLRs) are central receptors of the innate immune system 
which drive host inflammation and adaptive immune responses upon detection of 
invading microbes. Drugs targeting TLRs are of considerable interest as potential 
inflammatory regulators, vaccine adjuvants, and novel immunotherapeutics. Among 
human TLRs, TLR10 is the only remaining family member without a defined agonist or 
function. Phylogenetic analysis reveals that TLR10 is most related to TLR1 and TLR6, 
both of which mediate immune responses to a variety of microbial and fungal 
components in cooperation with TLR2. Knowledge gained of this orphan receptor is 
useful to fully understand the function of TLR2 subfamily, which comprises TLRs 2, 1, 6 
and 10. The primary objective of this doctoral dissertation research is to define the innate 
immune sensing function of TLR10 and understand the mechanisms responsible for 
ligand recognition within the TLR2 subfamily. 
Chapter One introduces the general field of innate immunity and reviews the 
current knowledge on TLRs, including structure and function, signaling pathways as well 
as signaling regulation of these receptors with an emphasis on the TLR2 subfamily. 
Chapter Two describes a high-throughput chemical library screen developed to 
uncover the ligands of TLR10 and novel TLR2 agonists. A synthetic chemical library of 
24,000 compounds was screened using an IL-8 driven-luciferase reporter in cells 
expressing TLRs 2, 1, 6 and 10. The screen failed to discover TLR10 ligands, but yielded 
several novel TLR2 dependent activators that utilize TLR1, TLR6, or both as co-
receptors. These novel small molecule compounds are aromatic in nature and structurally 
unrelated to any known TLR2 agonists. Two of the most potent compounds exhibit 
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species specificity and are inactive toward murine peritoneal macrophages.  Mutational 
analysis reveals that while the central extracellular region of TLR1 is required for 
stimulation, there are subtle differences in the mechanism of stimulation mediated by the 
synthetic compounds in comparison to natural lipoprotein agonists. The three most potent 
compounds stimulate TNF-α production form human peripheral blood monocytes.  The 
implication of these results and the potential importance of the novel TLR2 agonists are 
also discussed (Guan et al.  Journal of Biological Chemistry. 2010 July 30, 285: 23755-
23762). 
Chapter Three focuses on the identification of TLR10 ligands and characterization 
of sensing mechanisms by this receptor. The generation and analysis of chimeric 
receptors, containing the extracellular recognition domain of TLR10 and the intracellular 
signaling domain of TLR1, revealed that TLR10, in cooperation with TLR2, senses 
triacylated lipopeptides and a wide variety of other microbial-derived agonists shared by 
TLR1, but not TLR6. TLR10 requires TLR2 for innate immune recognition and these 
receptors colocalize in the phagosome and physically interact in an agonist dependent 
fashion. Computational modeling and mutational analysis of TLR10 show preservation of 
the essential TLR2 dimer interface and lipopeptide binding channel found in TLR1. Co-
immunoprecipitation experiments indicate that, similar to TLR2/1, TLR2/10 complexes 
recruit the proximal adaptor MyD88 to the activated receptor complex. However, TLR10, 
either alone or in cooperation with TLR2, fails to activate typical TLR-induced signaling 
including NF-κB, IL-8 or IFN-β driven reporters (Guan et al. Journal of Immunology, 
2010 May 1;184(9):5094-103). This finding explains why I was unable to discover  
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synthetic ligands of TLR10 in Chapter Two. Interestingly, the novel chemical compounds 
are agonists recognized only by TLR2/1 and not by TLR2/10.  
Chapter Four describes the generation of monoclonal antibodies against the 
extracellular domain of TLR10. A total of 15 hybridoma lines were established that 
secrete monoclonal antibodies that bind strongly to TLR10, but to neither TLR 1 nor 
TLR6. The purified anti-TLR10 antibody was used to examine endogenous TLR10 
expression in human peripheral blood.  I found that granulocytes, natural killer (NK) cells, 
monocytes and T cells lack detectable expression of TLR10. However human B cells 
express high cell surface levels of this receptor, suggesting that TLR10 plays a functional 
role in the B cell lineage. 
Chapter Five summarizes major findings from the dissertation research, assesses 
their contribution and potential implications to the TLR field, and explores future 
research directions for understanding the biological roles of TLR10. 
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CHAPTER ONE 
INTRODUCTION 
The Innate Immune System 
Vertebrates are constantly exposed to microorganisms present in the environment 
and yet only occasionally develop perceptible diseases. Most invading pathogens are 
eliminated by protection mechanisms, the immune system, which evolved for this 
purpose. The mammalian immune system is divided into the innate and adaptive 
branches. The adaptive system, comprised of T and B lymphocytes, is remarkable in its 
capability to generate a specific response against virtually any foreign antigen. This is 
achieved through a huge repertoire of lymphocytes each bearing a unique antigen 
receptor, so that the entire pool of antigen receptors is very large and highly diverse. In 
the event of infection, an individual lymphocyte that encounters a proper antigen 
proliferates and differentiates into effector cells capable of binding to antigens or 
secreting a specific antibody. Clonal selection, together with long-lived memory cells 
produced to increase protection against subsequent re-infection with the same agent, 
makes the adaptive immune system absolutely necessary for the generation of a robust 
immune response (Janeway et al., 2005). However, there is a delay of 4-7 days before a 
sufficient population of antigen-specific cells is produced to provide protection. During 
this time, pathogens can flourish inside the body and damage the host if unchecked. The 
innate immune components, which include macrophages, dendritic cells, neutrophils, 
anti-microbial peptides and the complement system, constitute the first line of defense 
which provides immediate recognition and responses to invading microorganisms. 
Microorganisms that cross the epithelial barrier of the body are met immediately by the 
cells and molecules that can induce a rapid innate immune response. Phagocytic 
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macrophages offer direct killing of pathogens and also mediate the release of 
proinflammatory chemokines and cytokines that recruit more innate immune cells and 
proteins from local blood vessels to the site of infection, thus initiating the process of 
inflammation. In addition, clear evidence has shown that the innate immune response 
makes a crucial contribution to the activation of adaptive immunity (Medzhitov and 
Janeway, 2000). 
The innate immune response provides an initial discrimination between self and 
non-self. Innate immune recognition is mediated by a number of germline-encoded 
receptors which detect relatively invariant molecular patterns present on viruses, 
microbes, fungi, protozoans and helminths. These structures are called pathogen-
associated molecular patterns (PAMPs), and the receptors have been denoted as pattern-
recognition receptors (PRRs) (Akira et al., 2006). PRRs are expressed on a variety of 
innate immune effector cells, and once they sense a PAMP, inflammatory responses are 
immediately triggered which accounts for the rapid innate immune response. Moreover, 
the signaling from activated receptors induces the expression of co-stimulatory molecules 
on macrophages and dendritic cells (antigen-presenting cells, APCs) which subsequently 
generate effective adaptive immune responses. In the past two decades, several families 
of PRRs have been characterized and the understanding of PAMP recognition is rapidly 
growing. We will first take a closer look at PRRs in the innate immune system, a subset 
of which will be the focus of this thesis. 
Pattern Recognition Receptors 
Cellular PRRs can be broadly classified into transmembrane proteins such as 
Toll-like receptors (TLRs) and C-type receptors (CLR), and cytoplamic proteins such as 
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Retinoic acid-inducible gene I (RIG)-like receptors (RLRs) and NOD-like receptors 
(NLRs). Here we briefly review their ligands and function (Takeuchi and Akira, 2010).  
The best-characterized PRR family is the TLR family. Toll, the founding receptor 
of the TLR family, was originally described in the fruitfly as a component of embryonic 
development (Hashimoto et al., 1988). Later, it was shown to trigger the formation of 
antimicrobial peptides in response to fungal infection in the adult fly (Lemaitre et al., 
1996). It is now known that the Toll homologues, termed TLRs, are present from lower 
invertebrates to mammals and have a critical role in the defense against various infections. 
To date, ten TLRs have been identified in humans and twelve in mice. All TLRs are type 
I transmembrane proteins and are expressed either on the plasma membrane or 
endosomal membrane. They are characterized by an extracellular domain (ECD) 
containing leucine-rich repeats (LRRs), and a transmembrane region followed by a 
cytoplasmic signaling domain homologous to that of the interleukin-1(IL-1) receptor and 
termed the Toll/IL-1R (TIR) domain (Takeda et al., 2003). Different TLRs recognize 
distinct molecular patterns of microorganisms (Fig. 1.1). Cell-surface TLRs sense 
conserved microbial cell wall constituents, such as lipoproteins of bacteria and 
mycoplasma (TLRs 2, 1, and 6), lipopolysaccharide (LPS) of Gram-negative bacteria 
(TLR4) and flagellin of bacteria (TLR5). Endosomal TLRs, comprising TLRs 3, 7, 8 and 
9, detect nucleic acid ligands derived from viruses and bacteria, including double-
stranded RNA (dsRNA) (TLR3), single-stranded RNA (ssRNA) (TLR7) and dsDNA 
(TLR9). Recognition of the ligands by TLRs triggers signaling pathways leading to the 
activation of transcription factors such as NF-B, AP-1 and IRFs, which regulate the 
production of pro-inflammatory cytokines and type-I interferons (IFNs). TLRs can also 
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trigger activation of adaptive immune responses, including up-regulation of co-
stimulatory molecules essential for T cell activation, T cell differentiation and antibody 
responses (Pasare and Medzhitov, 2004). Individual TLRs activate different signaling 
cascades depending on the distinct combination of adapters involved (Brikos and O'Neill, 
2008). The ligand-TLR interaction and TLR signaling pathways will be expanded in the 
next section. 
CLRs are another class of transmembrane PRRs which are characterized by the 
presence of a carbohydrate-binding domain.  CLRs recognize mannose, fucose and 
glucan carbohydrates on the surfaces of microorganisms such as viruses, fungi and 
bacteria. Following ligand sensing, CLRs trigger internalization of the pathogen, 
expression of specific cytokines and subsequent antigen presentation which drives T cell 
differentiation (Geijtenbeek and Gringhuis, 2009). Two examples of CLRs are dectin-1 
and the mannose receptor, which are highly expressed in macrophages and dendritic cells 
and function directly as phagocytic receptors. 
The pathogens that invade the cytosol are detected by cytoplasmic PRRs, 
including RLRs and NLRs. Both receptor families have received recent attention because 
of their roles in detection of viral and bacterial infection as well as the activation of 
inflammatory protein complexes in response to pathogens. The RLR family is composed 
of three members: retinoic acid-inducible gene I (RIG-1), melanoma differentiation-
associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP-2) 
(Takeuchi and Akira, 2009). These proteins all possess a central helicase/ATPase domain 
which is responsible for the recognition of specific RNA patterns generated during viral 
infection, such as ss/ds RNA structure patterns associated with ssRNA viruses and some 
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dsDNA viruses.  Ligand engagement of RLRs leads to the activation of IRFs and NF-B, 
which coordinate the production of type 1 IFNs (Rehwinkel and Reis e Sousa, 2010). On 
the other hand, the NLR family is composed of more than 20 members that detect 
intracellular pathogens and stress signals. The receptors in this family share the 
characteristic arrangement of a C-terminal LRR domain, a central nucleotide-binding 
oligomerization domain (NOD) and an N-terminal effector domain (Kanneganti et al., 
2007). Among this family, NOD1 and NOD2 detect portions of bacterial peptidoglycan 
and subsequently activate NF-B.  Another set of NLRs, upon activation, induce the 
assembly of the inflammasome complex and drive processing of inflammatory cytokines 
(Ting et al., 2010). While cytoplasmic PRRs have emerged as critical components of the 
innate immune response (most notably, the processing of pro-IL-1β), several questions, 
including mechanisms of ligand sensing, receptor structure, signaling pathways, as well 
as the interplay with TLRs, remain to be clarified in the near future.  
TLR Structure and Function 
Our knowledge of the TLR family has been growing rapidly over the past decade. 
Structural studies have begun to reveal how individual TLRs can distinguish different 
PAMPs, and the dissection of signaling pathways has shown how TLRs elicit 
inflammatory responses. Here we will highlight these recent advances. 
The ECDs of TLRs, which are responsible for binding various PAMPs, contain 
19-25 tandemly arranged LRRs. Each LRR is 20-30 amino acid-long and contains a 
conserved LxxLxLxxN motif with the remaining residues being more variable. The LRRs 
of TLRs form a solenoid structure with β strands and either loops or helical structures on 
the concave and convex surface, respectively (Bella et al., 2008). As mentioned 
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previously, different TLRs recognize structurally- and chemically- diverse molecular 
patterns of microorganisms. The recently solved crystal structures of ligand-bounded 
ECDs of several TLRs provide clues to the mechanisms of ligand recognition.  
Most TLRs form homodimers upon ligand binding. The well-studied TLR4, 
together with an accessory molecule called myeloid differentiation factor 2 (MD2), 
recognizes LPS of Gram negative bacteria. The lipid A portion of enteric bacterial LPS is 
the biologically active part and is composed of phosphorylated diglucosamine with four 
primary and two secondary acyl chains (Jin and Lee, 2008). The crystal structure of 
TLR4/MD2/LPS complex revealed that LPS binding induces the formation of a receptor 
multimer with two complexes of TLR4/MD2/LPS arranged symmetrically in an m-
shaped structure. Five of the lipid chains of LPS are accommodated by a hydrophobic 
pocket of MD2 and the sixth one is in contact with both TLR4 and MD2 (Park et al., 
2009).  
Among the TLRs localized in endosomal compartments, only the crystal structure 
of TLR3 bound to its ligand, dsRNA, has been solved to date. The sugar phosphate 
backbone of a dsRNA, which is 40-50 bp in length, binds to both N-terminal and C-
terminal portions of the glycan-free convex surface of TLR3. The dsRNA bridges 
together two molecules of TLR3 which form a stable m-shaped dimer juxtaposed at the 
C-terminal ends (Liu et al., 2008a).  
Unlike the homodimer configuration for most TLRs, TLR2 forms heterodimers 
with either TLR1 or TLR6 and mediates responses to a wide range of agonists. TLR1 and 
TLR6 enable TLR2 to discriminate subtle structural differences within the agonists and 
therefore greatly increased the repertoire of agonists for TLR2. The TLR2/1 pair 
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recognizes bacterial triacylated lipoprotein. In contrast, the TLR2/6 heterodimer is 
responsible for sensing mycoplasma diacylated lipoprotein (Takeuchi et al., 2001; 
Takeuchi et al., 2002). The crystal structure of the ECDs of TLRs 2 and 1 in complex 
with a synthetic triacylated lipopeptide Pam3CSK4 reveals an m-shaped heterodimer of 
TLR2 and TLR1 coordinately bound to the ligand Pam3CSK4.  Two acyl chains of 
Pam3CSK4 insert into an internal pocket of TLR2, and the remaining amide-bound lipid 
chain occupies the hydrophobic channel in TLR1 (Fig. 1.2) (Jin et al., 2007). Recently, 
the crystal structure of TLR2/TLR6/diacylated lipopeptide complex revealed that the 
overall structure is very similar to that of TLR2/TLR1/ Pam3CSK4 except that the lipid 
channel in TLR6 is blocked by two bulky amino acids which may explain why the 
TLR2/6 complex is unresponsive to triacylated lipoproteins (Kang et al., 2009). More 
specifically, the ECDs of TLRs 2, 1 and 6 can be divided into three subdomains, N-
terminal, central and C-terminal. The central and partial C-terminal domains (LRR5-12) 
are unusual in that they lack the asparagine ladder needed to maintain the standard β-
sheet twist (the ladder is formed by strictly preserving relative positions of the conserved 
asparagines in each LRR), and the length of their LRRs is more variable. These unique 
LRR motifs create the lipopeptide-binding sites in TLR2 and TLR1, both of which are 
located at the heterodimer interface. Domain swapping experiments between TLR1 and 
TLR6 has also indicated that the central LRRs of these receptors are required for 
discrimination of different lipopeptide agonists (Omueti et al., 2005). Taken together, all 
structural studies have indicated that the sites of interaction between ligands and their 
respective TLRs are very different from one to another, but they all form a stable m-
shaped dimeric arrangement between two subunits upon ligand binding. 
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Ligand-induced dimerization of ECDs brings together the two intracellular TIR 
domains of the receptors. TIR domains are comprised of a five-stranded parallel β-sheet 
(βA-βE) surrounded by five α-helical segments (αA-αE) (Xu et al., 2000). Multiple 
mutational and structural modeling studies have shown that the BB loop (connecting βB 
and αB) and the DD loop (connecting βD and αD) are important for driving the in the 
interaction between TLRs as well as between TLRs and adapters. The most prominent 
example is a proline-to-histidine mutation in BB loop of TLR4 is responsible for 
rendering C3H/HeJ mice insensitive to LPS (Poltorak et al., 1998). Similarly, the 
replacement of the homologous Pro 681 with His in the BB loop of human TLR2 disrupts 
signal transduction in response to zymosan and Gram-positive bacteria without disturbing 
the overall structure of the TIR domain (Underhill et al., 1999).  
TLR Signaling Pathways 
The TIR-TIR structure creates a scaffold for the recruitment of adapter proteins 
which mediate TLR signaling (Gay and Gangloff, 2008). Adapter proteins are a group of 
TIR domain-containing molecules, which includes MyD88 (myeloid differentiation 
antigen protein 88), TIRAP/Mal (TIR domain-containing adapter/MyD88 adapter like), 
TRIF (TIR domain-containing adapter inducing interferon-β), and TRAM (TRIF-related 
adapter molecule). Different combinations of adaptor molecules are activated by different 
TLRs resulting in various signaling outputs (Toshchakov et al., 2005). The TLR 
pathways are roughly categorized as MyD88-dependent and TRIF-dependent.  
MyD88 is the adapter employed by all TLRs except for TLR3. TLR2 and TLR4 
signaling requires TIRAP for the recruitment of MyD88 to the receptors. MyD88 
associates with IL-1R-associated kinases (IRAKs) to form signaling complexes. The 
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recently determined crystal structure of the MyD88-IRAK4 –IRAK2 complex showed 
that 6 MyD88, 4 IRAK4 and 4 IRAK2 molecules assemble to form a helical signaling 
tower, called a Myddosome complex, in which MyD88 recruits IRAK4 and the MyD88-
IRAK4 complex recruits IRAK2 (Lin et al., 2010). Following multiple phosphorylation 
events, IRAKs dissociate from MyD88 and interact with TNFR-associated factor 6 
(TRAF6), a protein which mediates the activation of NF-B and the MAPK (mitogen-
activated protein kinases) cascades. TRAF6 interacts with the ubiquitin-conjugating 
enzymes comprised of Uev1A and Ubc13 and itself becomes polyubiquinated, which 
consequently activates a complex of TGF-β-activated kinase 1 (TAK1), TAK1-binding 
protein 1 (TAB1), TAB2, and TAB3.  When TAK1 becomes ubiquininated, it 
phosphorylates the inhibitor of NF-B kinase (IKK) complex, composed of IKK-α, IKK-
β and NF-B essential modulator (NEMO). Subsequently, the IKK complex 
phosphorylates IB, an NF-B inhibitory protein. This event frees NF-B to translocate 
into the nucleus and activate the genes responsible for inflammatory responses. The 
TAK1 complex also interacts with the MAPK cascades, in which p38 and JNK are 
activated. They in turn lead to activation of another transcription factor complex, AP-1, 
which targets inflammatory-response genes. In addition, the MyD88-dependent pathway 
also activates interferon response factors (IRFs) from activated TLR7 and TLR9 
signaling. In this setting, when MyD88 forms complexes with IRAKs and TRAF6, the 
signaling cascade can proceed to the phosphorylation of different IRFs in a receptor and 
cell-specific way. The phosphorylated form of IRFs translocate to the nucleus to activate 
the expression of type 1 interferons, which induce hundreds of  genes involved in 
antiviral responses (Brikos and O'Neill, 2008). 
10 
 
TRIF is an additional proximal adaptor for TLR3 and TLR4 signaling. TLR4 
requires a bridging adaptor, TRAM, for activating TRIF. TRIF associates with two IKK-
related kinases, TRAF-family-member-associated NF-B activator (TANK) binding 
kinase 1(TBK1) and IKK. The complex then phosphorylates IRF3 and IRF7, leading to 
their activation and translocation into the nucleus, resulting in the induction of IFNs. 
TRIF has also been shown to activate to the NF-B pathway through TRAF3 and TRAF6 
(Brikos and O'Neill, 2008). 
Aside from the inflammatory pathways mentioned above, TLR signaling has been 
shown to regulate cytokine production as well as cell proliferation via MAPKs and PI3K 
(phosphoinositide 3-kinase). The MAPKs regulated by TLRs activate cAMP response 
element binding protein (CREB), which is a major transcription factor involved in cell 
metabolism. Moreover, several TLRs, including TLRs 2, 3 and 5, have been shown to 
interact with PI3K, whose downstream kinases are Akt/PKB (protein kinase B) and 
GSKs (glycogen synthase kinase 3). These kinases are involved in multiple cellular 
activities and appear to affect TLR signaling in both negative and positive ways 
depending on the cell type as well as the kind of cytokines produced (Li et al., 2010).  
Negative Regulation of TLR Signaling 
TLR activation is a double-edged sword. The immune response triggered by TLR 
engagement is indispensable for elimination of invading microorganisms and activation 
of adaptive immunity. However, excessive or inappropriate activation of TLR signaling 
can lead to severe inflammatory diseases and autoimmune diseases, such as septic shock 
and rheumatoid arthritis. Therefore, TLR signaling must be tightly controlled. More than 
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20 molecules have recently been showed to be involved in negative regulation of TLR 
signaling (Lang and Mansell, 2007), a few of which are briefly described here. 
Expression of natural soluble decoy receptors, which are proteins lacking the 
transmembrane and cytoplasmic domains of TLRs, have been described for TLR2 and 
TLR4. The soluble forms of these receptors have been shown to attenuate TLR2 and 
TLR4 signaling in response to bacterial lipopeptides and LPS, respectively,  presumably 
by competing with membrane-bound receptors for TLR ligands or by blocking the 
interaction between receptors and accessory molecules such as CD14 and MD2 (Iwami et 
al., 2000; LeBouder et al., 2003). 
There also exist transmembrane protein regulators such as ST2 (suppressor of 
tumorigenicity) and SIGIRR (single immunoglobulin IL-1 related protein). Both contain 
a TIR domain in their intracellular portion, and have been found to inhibit MyD88-
dependent signaling activated by TLR agonists. Current evidence suggests that ST2 acts 
as an inhibitor by sequestering the adaptors MyD88 and TIRAP (Brint et al., 2004). 
SIGIRR exerts its negative regulatory function possibly by interfering with the formation 
of receptor complexes and/or by attenuating the recruitment of signaling molecules, 
IRAK and TRAF6, to TLRs or IL1R (Wald et al., 2003). 
A number of intracellular negative regulators are capable of inhibiting TLR 
signaling at the adapter level. Examples include MyD88s, SARM (sterile α and Heat-
Armadillo motif), and IRAKM. MyD88s is an alternatively spliced, short form of MyD88 
and the inhibition of signaling is due to its failure to recruit IRAK4 (Burns et al., 2003). 
SARM is known to interact with TRIF and thereby prevent, either directly or indirectly, 
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its signaling (Carty et al., 2006). IRAKM is a member of the IRAK family and can inhibit 
the association of IRAK with TRAF-6 (Kobayashi et al., 2002).   
Another way to control TLR signaling is by regulating the expression level of 
receptors. Previous studies in the Tapping laboratory have shown that TLRs 2, 1 and 6 
expression levels are modulated upon ligand stimulation. Interestingly, in response to 
TLR agonists, TLR2 mRNA and protein level were rapidly up-regulated in human 
monocytes, while coreceptors TLRs 1 and 6 mRNA were down-regulated (Johnson and 
Tapping, 2007). This suggests a possible negative regulation of TLR2 activation. The 
increase in TLR2 expression could lead to the production of the soluble form of TLR2, 
which acts as a decoy receptor to dampen responses, while the decrease in coreceptor 
TLR1 and TLR6 expression would prevent cells from responding to TLR2 agonists 
(Johnson, 2008).  
The TLR2 Subfamily 
The TLR2 subfamily comprises TLRs 1, 2, 6 and 10. As previously mentioned, 
TLRs 2, 1 and 6 need to cooperate as TLR2/TLR1 or TLR2/TLR6 heterodimers to 
mediate signals in response to various agonists. Besides bacterial lipoproteins, TLR2 is 
also responsive to a wide variety of microbial structural components including zymosan 
yeast particles, lipoteichoic acid and peptidoglycan of Gram-positive bacteria, atypical 
LPS derived from Porphyromonas gingivalis, membrane lipoarabinomannans from 
mycobacteria, and type-II heat-labile enterotoxins from Escherichia coli, as well as a 
wide range of unknown agonists from a variety of pathogenic microbes (Hajishengallis et 
al., 2005; Takeda et al., 2003).  TLR2 has also been reported to detect diverse molecules 
of host origin associated with cell death and tissue damage, such as heat shock proteins, 
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hyaluronan fragments (degradation products of the extracellular matrix) and amyloids. 
However, for some TLR-stimulating ligands it is difficult to completely rule out possible 
contamination with other potent TLR agonists, such as lipoproteins or endotoxins 
(Erridge, 2010).  
There are additional co-receptors that can enhance TLR2 function in recognition 
of agonists and initiation of immune responses. For example, the myeloid receptor CD14 
transfers lipopeptides to TLR2 complexes, and increases cellular sensitivity to low 
concentrations of agonists (Nakata et al., 2006). The scavenger receptor CD36 acts as a 
TLR2/TLR6 coreceptor for sensing LTA and MALP-2 (macrophage-activating 
lipopeptide 2) (Hoebe et al., 2005). Integrin β3 is shown to form a complex with TLR2  
and contributes to the initiation of TLR2 responses to lipopeptides, LTA and zymosan 
(Gerold et al., 2008). Dectin-1 and mannose binding receptor have also been shown to 
collaborate with TLR2 in recognition of microbial components (Ip et al., 2008). 
TLRs 2, 1 and 6 are predominantly expressed on macrophages, monocytes, 
dendritic cells and B cells, along with other cells associated with innate immunity, such 
as endothelial and epithelial cells. Stimulation of these cells with TLR2 ligands induces 
the production of proinflammatory cytokines such as TNF-α, IL-8 and IL-6. A recent 
study has shown that TLR2 expressed on inflammatory monocytes can be activated by 
viruses leading to the induction of type I IFN (Barbalat et al., 2009). Such reactions were 
shown to occur only in response to viral ligands but not bacterial ones, and the signaling 
is unique to inflammatory monocytes. In addition, the induction of IFN requires 
internalization of TLR2, whereas signals leading to the production of TNF and IL-6 occur 
at the cell membranes.  
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Numerous studies have examined the function of the TLR2 subfamily. TLR2 
knock-out mice have an increased susceptibility to infection with Streptococcus 
pneumonia, Streptococcus aureus, Listeria monocytogenes and other bacteria, suggesting 
a general role of TLR2 in the protection of the host from infectious diseases (Wetzler, 
2003). Furthermore, receptor polymorphisms within the TLR2 subfamily are associated 
with various infections. For example, the R753Q variant of TLR2 is linked to increased 
susceptibility to tuberculosis as well as an acute rheumatic fever in children (Ogus et al., 
2004). The I602S variant of TLR1 is impaired in cell-surface trafficking, but provides 
protection against leprosy in a Turkish population (Johnson et al., 2007). Given the role 
of TLR2 in infectious diseases, TLR2 ligands have constituted important vaccine 
adjuvants to modulate immune responses. Synthetic lipopeptides, such as Pam3CKS4 and 
Malp-2, are currently under development as adjuvants. The Lyme disease vaccine 
contains an outer-surface lipopeptide A (OspA) from Borrelia burgdorferi, which is 
sensed primarily through TLRs 2 and 1 (Alexopoulou et al., 2002). Additional examples 
of antigens that are also TLR2 agonists include zwitterionic polysaccharides derived from 
group B Streptococcus and PorB porin from a nonpathogenic Neisseria strain (Gallorini 
et al., 2009; Liu et al., 2008b). In addition, some natural ligands of TLR2, when 
conjugated with a carrier protein antigen, have been shown to greatly enhance vaccine 
immunogenicity (Jackson et al., 2004).  
TLR2-dependent reactions also contribute to chronic inflammation. Studies in 
TLR2 knock-out mice support a role for TLR2 in the promotion of atherosclerosis, type 1 
diabetes, asthma, arthritis and ischemic reperfusion injury.  The potential ligands that 
stimulate TLR2 in these diseases could be microbial antigens as well as endogenous 
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products. In humans, a higher expression level of TLR2 has been demonstrated in 
patients with type 1 diabetes, rheumatoid rhinitis and inflammatory bowel diseases 
compared to healthy donors (Drexler and Foxwell, 2010; Ospelt and Gay, 2010). Taken 
together, these studies suggest that TLR2 may be a useful therapeutic target in preventing 
some of these diseases. Research on TLR2 antagonists and inhibitors of TLR2 signaling 
should provide more clues to the mechanisms by which TLR2 contributes to disease 
development. 
Human TLR10 
Despite extensive studies on TLRs in the past decade, TLR10 has remained an 
orphan member of the human TLRs whose ligand and function are not known. The 
studies described in this thesis mainly focus on this orphan receptor. TLR10 belongs to 
the TLR2 subfamily and is most closely related to TLR1 and TLR6 (Fig. 1.3). The genes 
for TLRs 10, 1 and 6 are tandemly arranged on chromosome 4. Phylogenetic analysis 
shows that the three genes arose from tandem gene duplication events of an ancestral 
gene. Phylogenetic analysis also predicts that TLR10 arose before the emergence of TLR1 
and TLR6 (Roach et al., 2005). Studies on chicken TLRs have revealed that several 
chTLR1s share a phylogenic clade with human TLR1-6-10 and when expressed, respond 
to lipopeptides with the cooperation of chTLR2 (Keestra et al., 2007; Temperley et al., 
2008), which suggested that the ligand recognition function predates the mammalian 
divergence of the TLR1-6-10 gene cluster. Thus, TLR10 has been speculated to be a 
potential partner for TLR2. In addition, given the fact that the TLR2 subfamily has 
evolved under strong purifying selection, the independent maintenance of the TLR10 
gene suggests a distinct function for this receptor (Roach et al., 2005).  
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The ECD of TLR10 contains 19 sequential LRR motifs flanked by an N-terminal 
cap and a C-terminal cap (Bella et al., 2008). Similar to TLR1 and TLR6, the sequence 
analysis of the TLR10 LRRs has revealed that the asparagine ladder is absent from 
LRR5-12 along with variable LRR lengths in this region, suggesting that TLR10 also has 
the three-domain architecture (N-term, central and C-term) in its extracellular portion (Jin 
and Lee, 2008).  
A recent crystal structure of the TLR10 TIR domain revealed a dimer in the 
asymmetric crystal packing unit. The dimer interface is mainly composed of the residues 
from the BB loop, and this configuration was predicted to provide an extensive interface 
for binding to adapter molecules (Nyman et al., 2008). However, it is uncertain if the 
homodimeric structure of the TLR10 TIR domain seen in the crystal corresponds to a 
biologically relevant arrangement since it exists as a monomer in solution. Moreover, the 
TIR domains of TLR1 and TLR2 were each solved as monomeric units. A docking study 
performed on the TIR domains of TLR1 and TLR2 proposed that the DD loop in TLR2 is 
in close contact with the BB loop of TLR1 to form the TIR-TIR heteodimer. In this 
configuration, the residues Gly 676, His 646 and Tyr 737 in TLR1 appear to interact with 
residues in the TIR domain of TLR2 (Gautam et al., 2006). Interestingly, these three 
residues are conserved in TLR10’s signaling domain. On the other hand, a sequence 
alignment of TLRs 1, 6 and 10 reveals that there are also substantial sequence differences 
in the TIR domains of TLR10 compared to the other two receptors, including significant 
changes within the BB loop as well as a number of substitutions and insertions. These 
analyses imply that TLR10 might be a partner for TLR2 but may possess a distinct 
signaling function.  
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TLR10 has a unique expression profile compared to TLR1 and TLR6, as 
measured by TLR10 mRNA. Unlike the wide expression pattern of TLR1 and TLR6, 
TLR10 expression appears to be more tissue- and cell type- specific, indicative of the 
functional divergence of TLR10 from the other two receptors. TLR10 mRNA is highly 
expressed in lymphoid tissues such as the spleen, lymph nodes, thymus, tonsils, and lung 
(Chuang and Ulevitch, 2001).  The analysis in isolated cell types has shown a high level 
TLR10 expression in the B cell lineage and weak expression in plasmacytoid dendritic 
cells (pDC), a cell type known to produce large amounts of IFNs upon recognition of 
viral components by TLRs (Bourke et al., 2003; Hasan et al., 2005; Hornung et al., 2002). 
A recent study has indicated that TLR10 is highly expressed in human regulatory T cells 
and that its expression is regulated through the cooperation between the transcription 
factors FOXP3 and NF-AT (Bell et al., 2007). Moreover, the expression level of TLR10 
is elevated in B cells following cell activation through the B-cell receptor, or following 
stimulation with microbial products (Bourke et al., 2003). 
The stimulation of B cells with TLR ligands, such as lipopeptides, LPS and CpG 
DNA, have been shown to induce cell proliferation, differentiation and IgM production 
(Ganley-Leal et al., 2006; Genestier et al., 2007). TLR signaling in B cells has also been 
shown to be required for inducing isotype switching in response to T-dependent antigens 
(Jegerlehner et al., 2007). Together, the expression of TLR10 on B cells and up-
regulation upon cell activation suggest a potential role for this receptor in B cell biology. 
Another unusual aspect about TLR10 is that it does not possess a mouse 
homologue due to the interruption of the mTLR10 gene by gaps and retroviral gene 
insertion (Hasan et al., 2005). However, TLR10 is conserved in rat, pig, cow and 
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macaque, among other mammals. The fact that TLR10 is a pseudogene in mice has 
prevented a functional assessment of this receptor using classical gene knock-out 
approaches. 
Thesis Outline 
Over the past 13 years, the importance of TLRs in driving innate and adaptive 
immune responses has been well established. TLR10 remains the only uncharacterized 
receptor among the human TLR family. Given its unusual expression profile and clear 
phylogenetic relationship with TLRs 2, 1 and 6, knowledge gained on this orphan 
receptor is useful to fully understand the function of the TLR2 subfamily and its possible 
linkage to adaptive immunity. The specific objectives of this study were to discover the 
ligand for TLR10, examine the mechanisms by which TLR10 recognizes its ligand, and 
analyze the role of TLR10 in innate immunity. 
Chapter Two of this thesis describes a high-throughput chemical library screen 
developed to discover synthetic ligands for TLR10 as well as novel TLR2 agonists. This 
screen examined IL-8 promoter induction of a luciferase reporter gene as a measure of 
receptor activity. Additionally, TLR10, together with TLRs 2, 1 and 6, was expressed on 
SW620 cells to maximize the chances of identifying TLR10 activators. Although the 
screening system failed to discover TLR10 ligands, it did successfully uncover several 
novel TLR2-dependent activators that utilize TLR1, TLR6, or both as co-receptors. These 
novel small molecule compounds are structurally unrelated to any known TLR2 agonists. 
Functional analysis of various TLR mutants reveals that there are subtle differences in the 
mechanism of stimulation mediated by the synthetic compounds in comparison to natural 
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lipoprotein agonists. The functional implication of these results and the potential biologic 
importance of the novel TLR2 agonists are also discussed.  
In studies described in Chapter Three of this thesis, I proceeded to define TLR10 
ligands using different approaches. The generation and analysis of chimeric receptors, 
containing the extracellular recognition domain of TLR10 and the intracellular signaling 
domain of TLR1, revealed that TLR10, in cooperation with TLR2, senses triacylated 
lipopeptides and a wide variety of other microbial-derived agonists shared by TLR1, but 
not TLR6. Interestingly, two of the most potent novel chemical compounds discovered in 
Chapter Two were found to be agonists recognized only by TLR2/1 but not by TLR2/10. 
Computational modeling and mutational analyses defined the mechanism by which 
TLR10 recognizes lipopeptide ligands. The results show that TLR10 preserves the TLR2 
dimer interface and the lipopeptide binding channel found in TLR1. However, TLR10, 
either alone or in cooperation with TLR2, failed to activate typical TLR-induced 
signaling including NF-κB, IL-8 or IFN-β driven reporters, which explains why I was 
unable to discover synthetic ligands of TLR10 in Chapter Two. Based on the results, it is 
concluded that human TLR10 cooperates with TLR2 in the sensing microbial products 
but possesses a unique signaling function. 
Chapter Four of this thesis describes my efforts to examine the expression of 
endogenous TLR10 protein. Through the development of anti-TLR10 monoclonal 
antibodies, a flow cytometric analysis of TLR10 in human whole blood cells was 
undertaken in these studies. The expression profile observed could be very useful for 
predicting an immune function for TLR10. Finally, Chapter Five integrates research 
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findings from previous chapters, and presents contributions and implications of this work 
for the TLR field.  
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Figures 
 
 
 
Figure 1.1. Human TLRs and their ligands1. 
  
                                                 
1 Thanks to Dr. Richard I. Tapping for the figure. 
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Figure 1.2. Structure of the TLR2/1/ Pam3CSK4 complex (Jin et al., 2007). The m-
shaped structure of the TLR2/1/ Pam3CSK4 complex.  Image was generated using PDB 
file 2z7x through PyMol software. 
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Figure 1.3. Phylogenetic analysis of hTLR family members. The phylogenetic tree was 
derived from an alignment of the amino acid sequences for hTLR members. 
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CHAPTER TWO 
IDENTIFICATION OF NOVEL SYNTHETIC TOLL-LIKE RECEPTOR 2 
AGONISTS BY HIGH THROUGHPUT SCREENING2 
Introduction 
Cellular innate immune responses drive the immediate release of pro-
inflammatory mediators that enable leukocytes to access the site of infection as well as 
responses of professional antigen presenting cells essential for generating effective 
adaptive immunity (Fearon, 1997; Medzhitov and Janeway, 1997b). The primary triggers 
of these responses are a family of pattern recognition receptors known as Toll-like 
receptors (TLRs). Humans possess 10 TLR family members, numbered 1 through 10, 
subsets of which are expressed in leukocytes and the epithelial cells of mucosal surfaces 
(Muzio et al., 2000; Zarember and Godowski, 2002). There are two major types of TLRs, 
those that reside in intracellular compartments and sense viral and bacterial nucleic acids 
and those that are expressed on the cell surface and sense outer membrane components of 
bacteria, fungi and protozoan organisms (Akira et al., 2006; Iwasaki and Medzhitov, 
2004). TLRs also recognize numerous molecules arising from damage to self tissues and 
this mode of TLR activation appears to play a central role in a number of non-infectious 
chronic inflammatory conditions (O'Neill et al., 2009; Zhang and Schluesener, 2006). 
While there are marked differences in signaling and gene induction across various TLRs, 
all cell surface TLRs engage a core signaling pathway culminating in the activation of 
NF-κB and the production of proinflammatory chemokines, cytokines and cell adhesion 
molecules (Kawai and Akira, 2007; O'Neill and Bowie, 2007). 
                                                 
2 Adapted from Guan, Y., Ayoade, K.O., Mutha, S.K., Hergenrother, P.J., Tapping, R.I. Journal 
of Biological Chemistry. 2010 July 30, 285: 23755-23762. 
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TLR2 is a cell surface receptor that senses a remarkable variety of bacterial, 
fungal and viral products as well as inflammatory self components. Among TLR2 
agonists, bacterial lipoproteins are by the far the most potent (Aliprantis et al., 1999; 
Brightbill et al., 1999). Additional TLR2 agonists comprise a diversity of structures 
including bacterial and fungal lipids, acylated sugars and proteins, unmodified protein 
complexes as well as certain polysaccharides (Miyake, 2007; Tapping, 2009). TLR2 
needs to form heterodimers with either TLR1 or TLR6 to generate signals and these 
TLR2/1 and TLR2/6 complexes discriminate different microbial products (Ozinsky et al., 
2000). For example, triacylated bacterial lipoproteins (mimicked by the lipopeptide 
Pam3CSK4) and diacylated lipoproteins (including the lipopeptide MALP-2, from 
mycoplasma) activate cells through TLR2/1 and TLR2/6 heterodimers, respectively 
(Takeuchi et al., 2001; Takeuchi et al., 2002). We have recently found that similar to 
TLR1, TLR10 also cooperates with TLR2 in the recognition of triacylated lipopeptides 
(presented in Chapter Three) (Guan et al., 2010). Additional co-receptors are essential for 
recognition of certain TLR2 agonists and thereby serve to increase the repertoire of 
agonists for this receptor (Miyake, 2007; Tapping, 2009). 
Given their therapeutic potential, there is considerable interest in pharmaceuticals 
that modulate TLR activation. TLR antagonists hold great clinical promise for the 
treatment of numerous inflammatory conditions and are under investigation for the 
treatment of viral infections, redirecting allergic helper T cell responses, and as anti-
cancer therapeutics (Kanzler et al., 2007; Makkouk and Abdelnoor, 2009; O'Neill et al., 
2009). Some TLR agonists also have proven safety and efficacy in humans as vaccine 
adjuvants and are currently in use in Europe (Casella and Mitchell, 2008; Kanzler et al., 
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2007). Synthetic lipopeptide agonists for TLR2 exhibit strong adjuvant activity when 
either mixed or directly conjugated to various antigens (Eriksson and Jackson, 2007; 
Moyle and Toth, 2008). In addition to lipopeptides, a variety of other natural TLR2 
agonists exhibit adjuvant activity including zwitterionic polysaccharides from Group B 
Streptoccoccus (Gallorini et al., 2009), Type IIb heat labile enterotoxin from 
enteropathogenic Escherichia coli (Liang et al., 2009b), and porin B from pathogenic 
Neisseriae spp. (Liu et al., 2008b). 
Despite their potential clinical utility, no high throughput screens for synthetic 
compounds that stimulate TLR2 have been reported.  In this chapter, the identification of 
novel synthetic TLR2 agonists by chemical library screening is presented. The structures 
of these small agonists are unrelated to any known natural agonists for TLR2. 
Mutagenesis studies indicate that TLR2/1 recognizes the compounds through 
mechanisms different from that of microbial lipopeptides. The compounds induce 
cytokine production in human peripheral blood monocytes suggesting they are worthy of 
further clinical development. 
Materials and Methods 
Reagents- D-Luciferin and coenzyme A trilithium salt were purchased from 
Sigma-Aldrich Corporation. Luciferin solution and luciferase assay buffer have been 
described elsewhere (Pazzagli et al., 1992). The synthetic bacterial lipopeptides 
Pam3CSK4, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-propyl]-(R)-cysteinyl-(lysyl)3-lysine 
and PamOct2CSK4, N-palmitoyl-S-[2,3-bis(octonoyloxy)-propyl]-(R)-cysteinyl-(lysyl)3-
lysine were obtained from EMC Microcollections. R isomer of MALP-2, S-[2,3-
bis(palmityloxy)-propyl]-(R)-cysteinyl-GNNDESNISFKEK (macrophage-activating 
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lipopeptide-2) was purchased from Alexis Biochemicals. Chemical compound A (N-
methyl-4-nitro-2-[4-(4-nitrophenyl)-1H-imidazolyl]aniline), Compound B (methyl 2-
[(anilinocarbonothioyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate), 
Compound C (ethyl 2- ({[(4-methoxyphenyl)amino]carbonothioyl}amino)- 4,5,6,7-
tetrahydro-1- benzothiophene -3- carboxylate), Compound E (N1-(4-chlorobenzyl)-N2-(4-
methylphenyl)-N2-(methylsulfonyl)glycinamide) and Compound F (N2-(4-bromophenyl)-
N1-(4-methoxybenzyl)-N2-(phenylsulfonyl)glycinamide) were individually purchased 
from Chembridge Corporation. Compounds were dissolved and diluted in dimethyl 
sulfoxide (DMSO). 
Plasmid Constructs- A common variant of human TLR1 represented by NCBI 
accession number AAI09095 is referred to as wild-type TLR1 in this paper and was used 
as the basis for generating various chimeric variants and mutants. The generation of 
TLR1 and TLR6 chimeric receptors were described previously (Omueti et al., 2005). The 
P315L polymorphic variant of TLR1 was generated as previously described based on the 
technique of overlap extension PCR (Omueti et al., 2007). TLR1 point mutants were 
generated by random mutagenesis using error-prone PCR (Cirino et al., 2003). Briefly, 
the central region of TLR1 was excised from a modified FLAG-tagged TLR1 construct 
with XbaI (underlined letters) sites flanking LRRs 9-12 (Omueti et al., 2005). Error prone 
PCR was performed on this fragment using forward 5’-
CCAATCTAGAAACAACTTGGAATTCTTTCATTAGGATCC-3’ and reverse 5’-
CCAATCTAGATTGTTTAAGGTAAGACTTGATAAGTTTGG-3’ primers. Error prone 
fragments were reinserted into TLR1 and the clones were screened by Clone Checker 
(Invitrogen, Carlsbad, CA) and verified by DNA sequencing. Screening of the library 
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revealed several TLR1 variants (V311E, F314D, Q316K, Y320N, E321V, I328N, 
V399D) with reduced responses to Pam3CSK4 (Guan et al., 2010; Liang et al., 2009a). 
Cell Culture- All cultured cells were grown at 37°C in a humidified environment 
containing 5% CO2. Human colonic epithelial SW620 cells and murine macrophage 
RAW 264.7 cells were cultured in RPMI 1640 medium containing 10%(v/v) fetal bovine 
serum (FBS) and 2mM L-glutamine. Murine peritoneal macrophages were cultured in 
RPMI 1640 medium supplemented with 10%(v/v) FBS, 2mM L-glutamine, 100μg/ml 
streptomycin and 100U/ml penicillin. Human peripheral blood monocytes were cultured 
in RPMI 1640 medium supplemented with 10% autologous plasma and 2mM L-
glutamine. 
Chemical Library Screening- The chemical library was composed of 
approximately 24,000 compounds, among which 9,000 were from a private collection of 
the Department of Chemistry at the University of Illinois, and the rest were from 
Chembridge Corporation. All the compounds were kept in dimethylsulfoxide (DMSO) at 
10mM in a 384-well plate format. The human colonic epithelial cell line SW620 was 
transiently co-transfected with TLRs 1, 2, 6 and 10 along with a firefly luciferase reporter 
driven by the IL-8 promoter in a 10-cm tissue culture dish. One day post transfection, 
cells were trypsinized and reseeded into 384-well plates (Corning Corp., Corning, NY) at 
a density of approximately 104 cells per well in a total volume of 20 μl. The next day 
chemical compounds were added into each well using a 384-pin transfer apparatus which 
delivered 0.2~1μl of each compound at an approximate concentration of 100μM. Each 
plate contained wells treated with DMSO alone as a negative control as well as 
Pam3CSK4 and MALP-2 as TLR2 agonist positive controls. The cells were incubated 
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with individual compounds and controls for at least 6 hours followed by cell lysis in a 
volume of 20μl. Luciferase values were normalized to DMSO-treated cells to determine 
relative cell activation levels. Compounds with greater than 2.5 fold activity over DMSO 
alone were selected for a second round of screening. A total amount of 217 compounds 
were retested for TLR-dependent activity in SW620 cells transfected with the TLRs 
against those transfected with the empty expression vector pFLAG-CMV. 
Transient transfection assays- SW620 cells were cotransfected with various TLR 
combinations along with an IL-8 promoter driven firefly luciferase reporter and a Renilla 
luciferase transfection control reporter. The amount of DNA used for transfection was 
20ng/ml for TLR2, 180ng/ml for TLR1, TLR6, TLR10 or TLR1 variants, 150ng/ml for 
IL-8 driven luciferase gene and 50ng/ml for Renilla control. Transfection was mediated 
by using Fugene6 (Roche Applied Science, Indianapolis, IN) at a lipid volume to DNA 
weight ratio of 4:1. Two days after transfection, cells were stimulated with indicated 
agonists for at least 6 hours and cell lysates were collected. Luciferase enzyme activities 
were measured using the dual-luciferase reporter assay system (Promega, Madison, WI). 
The values of firefly luciferase were first divided by that of Renilla luciferase values to 
normalize the transfection efficiency in different wells. All the values were then 
normalized to those of unstimulated cells with empty pFLAG-CMV vector and reporters 
to determine the relative luciferase activity. 
Stimulation of mouse peritoneal macrophages- All animal experiments were 
conducted in accordance with a protocol approved by the University of Illinois 
Institutional Animal Care and Use Committee. Wild Type C57BL6 mice were purchased 
from The Jackson Laboratory. TLR deficient mice were kind gifts of Dr. Shizou Akira 
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(Osaka University, Japan). Murine peritoneal macrophages were isolated from the mouse 
peritoneal cavity. Peritoneal cells were suspended in the medium described above and 
incubated in tissue culture plates for 2 hours. The non-adherent cells were removed by 
medium change. Adherent cells were initially seeded at 2 × 105 cells per well in 96-well 
cell culture plates. Cells were treated with indicated compounds, lipopeptides or DMSO 
controls for 16 hours. The concentration of mouse IL-6 or TNF-α in culture supernatants 
were determined by ELISA according to manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). 
Stimulation of human peripheral blood monocytes- Blood was obtained from 
healthy donors in accordance with a protocol approved by the University of Illinois 
Institutional Review Board. Human peripheral blood mononuclear cells were isolated 
from blood of healthy donors by Ficoll gradient centrifugation. CD14+ monocytes were 
further purified by magnetic negative selection (Miltenyi Biotec, Gladbach, Germany). 
The purified monocytes were cultured in the medium described above at density of 1 × 
105 cells per well in 96-well plates. Cells were treated with indicated compounds, 
lipopeptides or DMSO controls for 16 hours. The concentration of human TNF-α in 
culture supernatants were determined by ELISA according to manufacturer’s instructions 
(Invitrogen, Carlsbad, CA). 
Results 
Identification of novel TLR2 agonists by chemical library screening- The Tapping 
laboratory has previously shown that SW620, a human colonic epithelial cell line lacking 
endogenous expression of TLRs 1, 2, 6, and 10, can be used to reconstitute receptor 
activity following transient transfection (Omueti et al., 2005). In these transfection assays, 
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a firefly luciferase gene driven by the promoter of the IL-8 provides a robust reporter of 
TLR2/1 and TLR2/6 activity. To identify novel chemical compounds that activate TLR2 
heterodimers and discover the synthetic ligands for TLR10, I adapted this assay (co-
transfection of SW620 with TLRs 1, 2, 6 and 10 as well as the reporters) to a 384-well 
format and screened a chemical library comprised of 24,000 individual synthetic 
compounds. The primary screen, based on a 2.5 fold enhancement of luciferase activity, 
yielded 217 initial hits. These 217 compounds were comparatively rescreened against 
SW620 cells transfected with empty FLAG-CMV vector to exclude compounds that 
activate the reporter in a TLR-independent fashion. This rescreening identified a total of 
16 compounds with reproducible TLR2-dependent activation. In order to discriminate 
between TLR2/1, TLR2/6, and TLR2/10 mediated activation, cells transfected with 
different combinations of TLRs were examined for their response to the 10 most potent 
compounds (Fig. 2.1A). Most of the compounds were active toward cells co-expressing 
TLR2 and TLR1, while compound F was active toward cells expressing TLR2 and TLR6. 
Compound E appeared to be an agonist for both TLR2/1 and TLR2/6 receptor pairs. 
Neither TLR10 alone nor TLR10 paired with TLR2 was responsible for any cellular 
activation. The signaling of TLR10 was later found not to be able to activate the IL-8 
promoter (see Chapter Three for details). In addition, transfection of TLR2 alone did not 
render SW620 cells responsive to any of the compounds supporting the idea that TLR2 
requires other TLRs for activity.  
All of the active compounds have low molecular masses ranging from 300 to 500 
Daltons and are structurally unrelated to any known TLR2 agonists (Fig. 2.1B).  Two of 
the most active compounds, B and C, share the same core structure consisting of 3-
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carboxylbenzothiophene linked via a carbonothioylamino bridge to an anilino group. It 
should be also noted that compound E and F, which activate cells through TLRs 2 and 6, 
also contain the same core chemical structure comprised of N1-(benzyl)-N2-(phenyl)-N2-
(sulfonyl)glycinamide. The independent identification of compounds with similar core 
structures provides confidence that my screen has identified bona-fide TLR2 agonists. 
The compounds represent the physically smallest agonists for TLR2 reported to date.  
Compounds A, B and C are potent and TLR specific- Compounds A, B and C 
were selected for further analyses as they exhibited the highest levels of TLR-dependent 
stimulation. The activation of TLR2/1 was detected at compound concentrations as low 
as 30 nM (10 ng/ml) and stimulatory activities comparable to that of Pam3CSK4 were 
achieved when the concentration reached 3 μM (1 μg/ml) (Fig. 2.2). The does-response 
curves of compounds A and B continued to rise over a broad concentration and saturable 
levels of reporter activation were not observed even at 30 μM (10 μg/ml). In contrast, 
despite structural similarity to compound B, compound C appears to reach saturable 
activation levels at a concentration of 300nM (100 ng/mL). Notably, none of the three 
compounds exhibited any activity toward TLR2/6, even at the highest concentration 
tested. 
To confirm the specificity of the compounds for TLR1 and TLR2, I treated 
murine peritoneal macrophages derived from wild type, TLR1, TLR2, and TLR6 
knockout mice with the compounds and measured stimulation of IL-6 production (Fig. 
2.3A). The control stimuli were triacylated lipopeptide PamOct2CSK4 and diacylated 
lipopeptide MALP-2, which have been identified as strong murine TLR2/1 and TLR2/6 
agonists, respectively (Buwitt-Beckmann et al., 2006; Takeuchi et al., 2001).  As 
33 
 
expected, macrophages from both TLR2 and TLR6 deficient mice were unresponsive to 
MALP-2 stimulation while those from TLR1 deficient mice responded well. Conversely, 
the triacylated lipopeptide PamOct2CSK4 showed reduced activity toward both TLR1 and 
TLR2 deficient cells but not TLR6 deficient cells. Compound A activated murine 
macrophages in both a TLR1 and a TLR2 dependent manner confirming its specificity 
toward these two receptors. In contrast, compounds B and C did not stimulate cytokine 
production even from macrophages derived from wild type mice. These results suggest 
that compounds B and C activate human but not mouse TLRs. To confirm this finding I 
examined the activity of the compounds toward RAW 267.4 cells (Fig. 2.3B). While 
compound A was active, compounds B and C failed to induce TNF-α production in this 
murine derived macrophage cell line. These results show that compound B and C exhibit 
species-specific activity for human, but not mouse TLR2/1. While inactive, neither 
compounds B or C were observed to have antagonistic activity for mouse TLR2 (data not 
shown). 
Compounds A and B do not antagonize or synergize with lipopeptides- Given the 
distinct structural features between the compounds and the lipopeptide agonists, I next 
tested the ability of these agonists to exhibit synergy in the activation of TLR2/1. Cells 
co-expressing TLRs 2 and 1 were stimulated with various concentrations of Pam3CSK4 
together with a constant concentration of compound A or compound B (Fig. 2.4A). An 
additive response was observed suggesting a lack of any synergistic interaction. As the 
concentration of Pam3CSK4 exceeded 10 ng/ml, the more potent stimulatory effect of 
Pam3CSK4 began to overshadow that of the compounds suggesting that the former has a 
higher binding affinity for TLR2/1 compared to the latter. Given their weaker activity, I 
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next examined whether the compounds could act as antagonists toward Pam3CSK4. To 
this end, cells were incubated with compound A or compound B for 30 minutes prior to 
stimulation with Pam3CSK4 (Fig. 2.4B). No inhibition was observed suggesting that the 
weaker stimulatory activity of the compounds was due to either weaker receptor affinity 
and/or occupation of unique binding sites on the receptors compared to the lipopeptides. 
While compound A and compound B are structurally distinct small-molecule activators, I 
have observed that they do not exhibit synergism or antagonism with respect to each 
other (data not shown). 
The central LRRs of TLR1 are essential for activation by the compounds- The 
Tapping laboratory have previously found that the central LRRs of TLR1 and TLR6 are 
responsible for discriminating between Pam3CSK4 and MALP-2 agonists, respectively, 
using domain swapping experiments in which LRRs were exchanged between these two 
receptors (Omueti et al., 2005). In this approach, all of the chimeric receptors maintain 
activity toward one of the lipopeptide agonists, indicating that in all cases the solenoid 
structure is preserved. To define the region of the extracellular domain in TLR1 
responsible for compound recognition, I examined the ability of the compounds to 
activate the chimeric receptor constructs in conjunction with TLR2 following transient 
transfection in SW620 cells (Fig. 2.5). As observed previously, wild type TLR1, in 
cooperation with TLR2, mediated robust responses to both compounds and Pam3CSK4. 
An N-terminal exchange construct T6(1-8)/T1, in which LRRs 1 through 8 of TLR1 were 
replaced with those of TLR6, was activated by the compounds and by Pam3CSK4. 
However, when the N-terminal replacement of TLR1 with TLR6 was extended to LRR12 
(construct T6(1-12)/T1), responses to all the agonists were completely lost. Additionally, 
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the reverse chimera T1(1-8)/T6, in which the first 8 LRRs of TLR6 were replaced with 
those of TLR1, was completely inactive toward all the agonists. Only when the first 12 
N-terminal LRRs of TLR1 were replaced with those of TLR6, did the resulting chimera 
T1(1-12)/T6 exhibit any activity toward the compounds and Pam3CSK4. It is worthy to 
note that the activation of T1(1-12)/T6 by compounds B and C was barely detectable. 
Finally, an internal swap chimera T1(6-17)/T6, in which LRRs 6 through17 of TLR6 
replaced those of TLR1, restored activity to all of the agonists. Taken together, these 
results indicate that similar to Pam3CSK4, the central extracellular domain comprising 
LRRs 9 through 12 of TLR1 is required for recognition of compound agonists. 
Compound-mediated activation of TLR2/1 is distinct from that of Pam3CSK4- 
Sequential LRR motifs form spring-like structures in which each LRR contributes a 
single turn with hydrophobic residues buried in the interior of the solenoid (Bella et al., 
2008; Jin and Lee, 2008). The crystal structure of the human TLR2/TLR1/Pam3CSK4 
complex reveals that the TLR1 and TLR2 solenoids form an m-shaped heterodimer in 
which the Pam3CSK4 ligand is coordinately bound. In the complex the two acyl chains of 
the diacyl glycerol unit of Pam3CSK4 are bound to a hydrophobic pocket of TLR2, 
whereas the third amide-bound acyl chain of the ligand interacts with a more narrow 
hydrophobic channel within the central region of TLR1 (Fig. 6A). In addition to sharing 
ligand binding, the receptors themselves are predicted to make direct contacts in this 
central region through a number of hydrogen bonds and hydrophobic interactions (Jin et 
al., 2007). 
Given the importance of the central LRRs in the TLR2/1/lipopeptide complex, a 
random mutagenesis library was generated in which TLR1 variants with single amino 
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acid changes were created. Through screening of the library several TLR1 variants were 
identified that affect responses to Pam3CSK4 (Liang et al., 2009a). To further explore the 
mechanisms by which TLR recognition of the small compounds and Pam3CSK4 leads to 
cellular activation, I compared the responses of TLR1 point mutant receptor variants to 
the different TLR2/1 synthetic agonists. Tyr320 of TLR1 is predicted to make 
hydrophobic interactions with residues Leu324 and Tyr323 of TLR2. There are also 
predicted ionic interactions between Glu321 of TLR1 and Arg321 of TLR2 (Fig. 2.6A). 
The individual substitution of these TLR1 residues results in an overall partial loss of 
responses to both Pam3CSK4 and the compounds (Fig. 2.6B). A charged amino acid 
substitution at Val339 of TLR1, which engages the center of a hydrophobic patch of 
TLR2 comprised of Phe322, Phe 349 and Leu371, resulted in a dramatic and uniform loss 
of receptor activity to all the agonists. These results suggest that unimpaired receptor 
dimer interaction is required to mediate efficient responses to both the chemical 
compounds and to the lipopeptides. 
Several of the point mutants involve amino acid changes at positions 311 to 316 
of TLR1. These residues form a loop that contributes to the receptor dimer interface and 
also reside at sites of interaction with the lipopeptide (Fig. 2.6A). In the 
TLR2/1/lipopeptide complex, Val311 of TLR1 appears to make hydrophobic contacts 
with a hydrophobic patch of TLR2 contributed by Leu350, Pro352 and Tyr376. A TLR1 
variant in which Val311 of the loop is replaced with Glu retained activity toward 
Pam3CSK4 but exhibited highly attenuated responses to compound A and partial activity 
to compounds B and C (Fig. 2.6B). When Phe314, which appears to orient the protein 
backbone of the loop through intramolecular contacts with TLR1, is substituted with a 
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charged Lys residue the responses to either lipopeptide or compound A are almost 
completely abolished, but those to either compound B or compound C are partially 
preserved. Pro315Leu is a naturally occurring polymorphism of TLR1 that exhibits 
highly attenuated responses to Pam3CSK4 (Omueti et al., 2007). This proline residue 
resides in the channel that accommodates the peptide and is predicted to engage TLR2 
through hydrophobic interactions (Jin et al., 2007). Similar to lipopeptides, this receptor 
variant also displayed a highly attenuated activity to compound A, but responses to 
compounds B and C were partially retained (Fig. 2.6B). In addition to the acyl chains, 
TLR1 also interacts with Pam3CSK4 by forming a hydrogen bond between the side chain 
of Gln316 and the amide oxygen of the lipopeptide. The fact that substitution of Gln316 
with lysine abrogated Pam3CSK4 stimulation, indicates that this is an important receptor-
ligand interaction. Interestingly, this TLR1 variant retained greater than half maximal 
responses to all the chemical compounds. Taken together, the results suggest that while 
the gross configuration of the TLR2/1 heterodimer in similar for the different agonists, 
there are subtle differences at the receptor interface important for driving cellular 
activation. 
The compounds stimulate TNF-α production from human peripheral monocytes- I 
next evaluated the ability of compounds A, B and C to activate human monocytes 
isolated from peripheral blood of healthy donors (Fig. 2.7). I found that the compounds 
dose dependently activated TNF-α production in human monocytes. While all three 
compounds induced TNF-α release at micromolar concentrations, compounds B and C 
exhibited weaker activity than compound A. The fact that the compounds are able to 
38 
 
activate primary human cells suggests that they may have clinical utility, perhaps as 
novel vaccine adjuvants. 
Discussion 
In this study, I have adapted a cell based TLR2 activity assay to a format that 
permits screening of small chemical libraries for novel TLR2 agonists. The assay utilizes 
an SW620 epithelial cell line expressing TLRs 1, 2, 6 and 10 as well as a luciferase 
reporter driven by the promoter of the IL-8. This assay remains sensitive and robust, 
exhibiting a 30-50 fold increase in luciferase activity in response to TLR2 lipopeptide 
agonists, despite adaptation to a 384-well format in which measurements are derived 
from as few as 5,000 cells per well. An initial screen of 24,000 compounds provided 217 
hits and a secondary screen, which permits as assessment of TLR2 dependency, revealed 
5 compounds with greater than 5 fold activity. All 5 compounds share 5 or 6 atom-ring 
structures including phenol, thiophene and imidazole groups, which are absent in TLR2 
natural agonists. Compounds B and C share a core (anilinocarbonothioyl) amino-
benzothiophene structure. Similarly, compounds E and F are both sulfonylglycinamides 
with terminal phenyl groups. These compounds are the smallest TLR2 agonists identified 
to date and only slightly larger than the imidazoquinoline agonists for TLR7 and TLR8. 
The independent identification of structurally similar compounds from a diverse chemical 
library serves to validate the screening assay and demonstrates that it presents a robust 
method of identifying novel TLR2 agonists. 
TLR activation involves agonist-induced receptor dimerization. This event brings 
together two receptor signaling domains which serve as platforms for the recruitment of 
adaptor molecules required to initiate signaling (Monie et al., 2009; O'Neill and Bowie, 
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2007). The structure of the TLR2/1/Pam3CSK4 complex reveals coordinate binding of the 
lipopeptide by both receptors in which two acyl chains are embedded within a 
hydrophobic pocket of TLR2 with the third amide linked acyl chain bound within a 
hydrophobic channel of TLR1 (Jin et al., 2007). Additionally, hydrogen bonds between 
the glycerol and peptide backbone of Pam3CSK4 and the TLRs, as well as direct contacts 
between the receptors themselves at the receptor dimer interface, contribute to stable 
heterodimer formation. As diacylated lipopeptide agonists of TLR2/6 lack the third amide 
linked acyl chain, the TLR2/6/Pam2CSK4 complex relies more heavily on these latter 
interactions. Indeed, the crystal structure reveals that the hydrophobic channel of TLR6 
cannot accommodate long acyl chains due to blockage by two phenylalanine residues 
(Kang et al., 2009).  
Assessment of both domain exchange and point mutants revealed that, similar to 
lipopeptides, activation by the compounds requires the central LRRs of TLR1. Strikingly, 
TLR1 residues Tyr320, Glu321 and Val339, which are farther removed from the 
Pam3CSK4 binding site and appear to interact with TLR2 at the receptor dimer interface, 
make similar contributions to receptor activity independent of the agonist used. Taken 
together, these results suggest that the orientation and interactions between TLR1 and 
TLR2 in the activated heterodimer complex are similar irrespective of the agonist.  
Despite these similarities, the lipopeptide and chemical agonists differ in their 
ability to activate TLR1 variants that possess individually altered residues located in the 
loop of LRR11. These residues line the lipopeptide binding pocket and many are 
presumed to interact with TLR2 at the receptor dimer interface. The stronger inhibitory 
effect of the Gln316 mutation on Pam3CSK4 activation versus the compounds is 
40 
 
supported by the crystal structure which predicts a hydrogen bond between this residue 
and the peptide backbone of the lipopeptide. However the differential effects of 
individual TLR1 mutations at Val311, Phe314 or Pro315 are harder to explain and 
suggest that the contribution of these residues, either to a ligand binding pocket or to 
interactions at the receptor dimer interface, is subtly different dependent upon the agonist. 
As expected however, the effect of TLR1 mutations on the activity of the structurally 
related compound B and C agonists is similar. Interestingly, compounds B and C were 
inactive toward murine cells and thus exhibit species specificity for human but not mouse 
TLR2/1. To my knowledge, the only other species specific TLR2 agonist reported to date 
is a tri-lauroylated lipopeptide which stimulates mouse but not human TLR2 (Grabiec et 
al., 2004). 
The activity of the TLR1 point mutants, and the fact that the bulky phenyl groups 
of the compounds are too large to be accommodated by the hydrophobic channel of 
TLR1, suggests that the compounds bind directly within the interface of the TLR2/1 
heterodimer. It is important to note that even the most active compounds identified in my 
screen are approximately 3 orders of magnitude less potent in the TLR2 activation assay 
than the lipopeptide control agonists (Fig. 2.2). This is perhaps not surprising given that 
none of the screened chemical libraries contained compounds with long acyl chains 
which are known to contribute to ligand binding and heterodimer formation. Similarly, a 
wide variety of naturally occurring agonists which lack acyl chains are far less potent 
TLR2 activators than bacterial lipopeptides and lipoproteins (Miyake, 2007; Tapping, 
2009). Since TLR2 mediates responses to such a wide range of agonists, additional ligand 
docking analyses, mutagenesis studies and crystal structures will be required to fully 
41 
 
understand the full scope of interactions that can ultimately drive heterodimer formation 
and activation of TLR2 complexes.  
The incorporation of TLR agonists in vaccine development represents a promising 
mechanism to boost immune responses to infectious agents and tumor antigens. However, 
inflammatory toxicity associated with strong TLR agonists limits their broad application 
(Hauguel and Hackett, 2008; Lahiri et al., 2008). The TLR2-dependent adjuvants under 
development include lipopeptides, zwitterionic polysaccharides and larger bacteria-
derived proteins (Eriksson and Jackson, 2007; Gallorini et al., 2009; Liang et al., 2009b; 
Liu et al., 2008b; Moyle and Toth, 2008). While I have not tested compounds A, B and C 
for adjuvanticity, I have observed that these synthetic TLR2 agonists weakly induce 
TNF-α production from human monocytes (Fig. 2.7). I have also found that even at high 
concentrations the compounds fail to activate TLR2 as potently as lipopeptides (Fig. 2.2). 
This may be of clinical benefit as such weak or partial agonists often avoid the toxicity 
associated with strong inflammation. For example, the lipopolysaccharide analogue 
monophosphoryl lipid A is a weak or partial TLR4 agonist and an effective adjuvant in 
Hepatitis B vaccine formulations approved in Europe and Argentina. The small size and 
defined chemistry of the compounds also favors direct conjugation to antigen, an 
approach with lipopeptide that elicits robust antibody responses to tumor antigens in mice 
(Ingale et al., 2007). 
In conclusion, the high-throughput screening assay developed in this study has 
uncovered novel synthetic small molecule TLR2 agonists. Next generation analogues of 
the compounds may exhibit pharmacologic and clinically favorable characteristics and 
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will enable a closer examination of the structure-function relationship between agonists 
and TLR2 complexes. 
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Figures 
 
 
Figure  2.1. Activity and structure of novel chemical agonists for TLR2. (A) SW620 cells 
were co-transfected with various combinations of TLRs and an IL-8 driven luciferase 
gene and seeded into a 384-well plate. Two days after transfection, cells were stimulated 
with the indicated compounds at a concentration of approximately 100 μM for at least 6 
hr. Cells were then lysed and luciferase activities were measured. All values were 
normalized to those of unstimulated cells with reporter and empty FLAG-CMV vector. 
Each bar represents the average of two independent experimental values. (B) The 
chemical structures of the novel TLR2 agonists. Dashed lines shown the common 
structures identified for certain pairs of compounds. 
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Figure 2.2. Compound A, B and C are potent TLR2/1 agonists. SW620 cells were 
cotransfected with vectors encoding the indicated TLRs, an IL-8 driven firefly luciferase 
gene and a Renilla luciferase control. Two days after transfection, cells were stimulated 
with different concentrations of compounds A, B or C for 6 hours and cell lysates were 
analysed for dual luciferase acitivity. After correcting for transfection efficiency using 
Renilla luciferase, all values were normalized to those of unstimulated cells transfected 
with empty FLAG-CMV vector. Error bars represent the standard deviation of three 
independent wells stimulated with the indicated concentration of agonist. 
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Figure 2.3. Compound A, but not B and C, induces IL-6 production in murine 
macrophages in a TLR1 and 2 dependent manner. (A) Murine peritoneal macrophages 
prepared from wild type, TLR1-/- , TLR2-/- and TLR6-/- were plated at the density of 
1x105 cells per well. Cells were then stimulated with 10 μg/ml of either compound A, B 
or C, 100 ng/ml of PamOct2CSK4 or 100 ng/ml of MALP-2 for 16 hours. IL-6 release 
was measured in the culture supernatant by ELISA. (B) RAW cells were plated at a 
density of 0.8x105 per well and were stimulated with 5 μg/ml of either compound A, B or 
C for 16 hours, and TNF-α release was measured in the culture supernatant by ELISA. 
Error bars represent the standard deviation of values obtained from 3 independent wells. 
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Figure 2.4. Compound A and B do not synergize or antagonize Pam3CSK4 activity. 
SW620 cells were transfected with TLR2, TLR1, IL-8 reporter and Renilla transfection 
control. (A) Two days after transfection, cells were stimulated with increasing 
concentrations of Pam3CSK4 alone or Pam3CSK4 along with either compound A or B (1 
μg/ml) for 6 hours. (B) Two days after transfection, cells were pre-treated with compound 
A or B (1 μg /ml) for 30min, followed by stimulation with increasing concentrations of 
Pam3CSK4 for 6 hours. Luciferase activity was measured as described before. The error 
bars represent the standard deviation of values obtained from three independent wells.  
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Figure 2.5. The central extracelluar region comprised of LRRs 9-12 of TLR1 is required 
for compound-mediated cell activation. SW620 cells were cotransfected with TLR2 and 
the indicated TLR1 chimeras, an IL-8-driven luciferase gene, and a Renilla transfection 
control. Cells were stimulated with 5 μg/ml of compound A, B or C or 20 ng/ml of 
Pam3CSK4 for 6 hours. Luciferase activity was measured as described before. Error bars 
represent the standard deviation of values obtained from three independent wells.  
 
48 
 
 
Figure 2.6. Compound-mediated activation of TLR2/1 is distinct from that of Pam3CSK4.  
(A) Electrostatic surface representations of the TLR1 and TLR2 heterodimer interface 
based upon the crystal structure of the TLR2/1/ Pam3CSK4 complex (Jin et al., 2007). 
PyMol software was used to split open the TLR2/1/lipopeptide complex and each TLR 
was rotated 90 degrees to display the dimer interfaces of TLR1 and TLR2. Negative and 
positive charges are shown in red and blue, respectively. The lipopeptide agonist 
Pam3CSK4 is repeated in stick form in both images with carbons, nitrogens, oxygens, and 
sulfur are colored in green, blue, red and yellow, respectively. Mutated amino acid 
residues of TLR1 along with corresponding residues on TLR2 that are presumed to make 
interactions are indicated. (B) SW620 cells were cotransfected with TLR2 and the 
indicated TLR1 mutants, an IL-8-driven luciferase gene, and a Renilla transfection 
control. Cells were stimulated with 5μg/ml of compound A, B or C or 20ng/ml of 
Pam3CSK4 for 6 hours. Luciferase activity was measured as described before. The error 
bars represent the standard deviation from three independent wells. The experiment was 
repeated three times without significant differences between replicates. A representative 
experiment is shown. 
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Figure 2.7. Compounds A, B and C induce TNF-α production from human monocytes. 
Human peripheral blood monocytes were cultured at a density of 1x105 cells per well 
with increasing concentrations of compounds A, B or C for 18 hours. TNF-α release was 
measured in the culture supernatant by ELISA. Error bars represent the standard 
deviation of values obtained from three independent well.  
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CHAPTER THREE 
HUMAN TOLL-LIKE RECEPTORS 10 AND 1 SHARE COMMON 
MECHANISMS OF INNATE IMMUNE SENSING BUT NOT SIGNALING3 
Introduction 
The innate immune system is the first line of defense in response to an invading 
pathogen. Cellular innate immune defenses are necessary for the direct killing of 
pathogens, and they also mediate the immediate release of pro-inflammatory mediators 
that enable immune cells to access the site of infection, as well as the responses of 
professional antigen presenting cells essential for generating effective adaptive immunity 
(Fearon, 1997; Medzhitov and Janeway, 1997a). Primary triggers of inflammatory and 
adaptive responses are the TLRs, a family of cell surface innate immune sensors that 
exist in organisms ranging from lower invertebrates to higher mammals. Mammalian 
TLRs alert the host to the presence of infection through direct recognition of conserved 
structural components of viruses, bacteria, fungi and protozoans (Akira et al., 2006; 
Iwasaki and Medzhitov, 2004). In addition to microbial and viral products, TLRs also 
sense molecules associated with damage to self tissues as well as host products of 
inflammation (Zhang and Schluesener, 2006). 
Humans possess 10 TLR family members, numbered 1 through 10, subsets of 
which are expressed in leukocytes and the epithelial cells of mucosal surfaces (Faure et 
al.; Muzio et al., 2000; Zarember and Godowski). In accordance with their role in host 
defense, monocytes/macrophages express most TLRs (Muzio et al., 2000), while the 
                                                 
3 Adapted from Guan, Y., Ranoa, D.R.E., Jiang, S., Mutha, S.K., Li, X., Baudry, J., Tapping, R.I.  
Journal of Immunology 2010 May 1;184(9):5094-103. 
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expression of individual TLRs in dendritic cells depends upon their subtype (Barton and 
Medzhitov; Kadowaki et al., 2001). The microbial agonists for TLRs include a wide 
variety of structures. For example, TLRs 3, 7, 8 and 9 respond to nucleic acids from both 
bacteria and viruses and these intracellular family members induce the expression of 
type-1 interferons that possess potent antiviral activities (Krieg and Vollmer, 2007; 
Uematsu and Akira, 2007). In contrast, TLRs 1, 2, 4, 5 and 6 sense outer membrane 
components of bacteria, fungi and protozoan organisms and these receptors are expressed 
on the surface of mammalian cells. Although most TLRs signal as homodimers, TLR2 
requires either TLR1 or TLR6 for activity (Ozinsky et al., 2000). TLR1/2 and TLR6/2 
heterodimers discriminate between different microbial products which include bacterial 
lipoproteins, bacterial lipoteichoic acids, non-enteric bacterial lipopolysaccharides, fungal 
phospholipomannans, protozoan glycophosphatidylinositol anchors and mycobacterial 
lipomannans and phosphatidylinositols (Akira et al., 2006). The cell surface TLRs engage 
a core signaling pathway leading to activation of NF-κB, AP-1 and other transcription 
factors that drive the production of proinflammatory chemokines, cytokines and cell 
adhesion molecules (O'Neill and Bowie, 2007).  
Despite extensive research on the TLRs, human TLR10 has remained an orphan 
receptor without a known agonist or function. TLR10 was initially cloned in 2001 and 
shares highest homology with both TLR1 and TLR6 (Chuang and Ulevitch, 2001). In 
mammals, TLRs 10, 1 and 6 genes are tandemly arranged and appear to have arisen from 
duplication events. Phylogeny supports the idea that TLR10 arose before the gene 
duplication that generated TLR1 and TLR6 (Roach et al., 2005; Zhou et al., 2007). 
Chickens possess two TLRs that share ancestral origins with the TLR1-6-10 cluster and 
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two additional TLRs that share origins with TLR2 (Temperley et al., 2008). The fact that 
these chicken TLRs mediate responses to lipopeptides through cooperative interactions 
indicates that this recognition function predates the mammalian expansion of the TLR1-6-
10 cluster (Hughes and Piontkivska, 2008).  The TLR2 subfamily is thought to have 
evolved under positive and balancing selection and among primates TIR domains appear 
to have undergone purifying selection (Ferrer-Admetlla et al., 2008; Nakajima et al., 
2008). The independent maintenance of TLR10 and its associated TIR domain suggest a 
distinct biological role for this receptor (Hughes and Piontkivska, 2008; Roach et al., 
2005).  
TLR10 is a somewhat unusual family member in that it is highly expressed in the 
B cell lineage suggesting that it plays a critical role in B cell function. The presence of 
sequence gaps and retroviral insertions reveals that mouse TLR10 is a pseudogene, a 
situation that precludes the generation and phenotypic assessment of a TLR10 knock-out 
mouse. In this chapter I report that human TLR10 shares a variety of agonists with TLR1 
including a number of cell surface components of bacteria and fungi. Similar to TLR1 
and TLR6, TLR10 requires TLR2 for recognition. However, I have found that TLR10 
lacks downstream signaling typically associated with other TLR2 family members. 
Materials and Methods 
Ethics Statement- Veterinary care was provided by the clinical and technical staff 
of the Division of Animal Resources at the University of Illinois at Urbana Champaign 
which is an AAALAC accredited facility. All animal experiments were approved by the 
University of Illinois Institutional Animal Care and Use Committee. 
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Reagents- Synthetic bacterial lipopeptides, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-
propyl]-(R)-cysteinyl-(lysyl)3-lysine (Pam3CSK4), S-[2,3-bis(hydroxy)-propyl]-(R)-
cysteinyl-(lysyl)3-lysine (PamCSK4), N-palmitoly-S-[2-hydroxy-3-
(palmitoyloxy)propyl]-(R)-cysteinyl-(lysyl)3-lysine (PamCysPamSK4), and S-[2,3-
bis(palmitoyloxy)-propyl]-(R)-cysteinyl-GNNDESNISFKEK (macrophage-activating 
lipopeptide-2 (MALP-2)) were purchased from EMC Microcollections (Tuebingen, 
Germany). The microbial-derived agonists, LPS derived from Porphyromonas gingivalis, 
heat-killed Acholeplasma laidlawii (HKAL), lipoteichoic Acid from Staphylococcus 
aureus (LTA-SA), and lipomannan from Mycobacteria smegmatis were purchased from 
Invivogen (San Diego, CA). Zymosan particles and heat-killed Staphylococcus aureus 
(HKSA) were purchased from Invitrogen Life Technologies (Carlsbad, CA). 
Mycobacteria membrane fractions were received from National Institute of Allergy and 
Infectious Diseases Contract N01 AI-75320 entitled "Tuberculosis Research Materials 
and Vaccine Testing". The Escherichia coli type II heat-labile enterotoxin LT-IIa B 
subunits (LT-IIaB) was from Dr. T. Connell (University at Buffalo, State University of 
New York, Buffalo, NY). 
The monoclonal anti-FLAG antibody, HRP-conjugated anti-Flag (M2) mAb and 
anti-hemagglutinin (HA) affinity gel were purchased from Sigma-Aldrich (St. Louis, 
MO). HRP-conjugated anti-HA Ab were purchased from Miltenyi Biotec (Auburn, CA). 
The anti-human TLR1 antibody (clone GD2.F4) and anti-human TLR2 antibody (clone 
T2.5) were obtained from eBioscience (San Diego, CA). The secondary antibody, Biotin-
conjugated donkey anti-mouse IgG (H+L) and a streptavidin-conjugated fluorophore 
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tertiary antibody were obtained from Jackson ImmunoResearch Laboratories (West 
Grove, PA). 
Plasmid constructs-The primers for construction of the plasmids in this study are 
listed in Appendix Table 1. All constructs were verified by complete sequencing of both 
strands of all recombinant insertions. 
CD4-TLRs—the CD4-TLR4 construct was a kind gift from Dr. Charles Janeway 
Jr (Yale University, New Haven, CT).  The coding region of mouse CD4 extracellular 
domain (ECD) was fused with that of the transmembrane (TM) and intracellular portions 
of TLR1, TLR2 or TLR10. Both PCR products were cloned together into pCDNA3.1. 
ENA-78 reporter—the promoter region (approximately 660bp) of human 
neutrophil-activating peptide (ENA-78) gene was amplified from human genomic DNA 
(Corbett et al., 1994). The PCR product was then cloned into the pGL3 basic vector 
(Promega, Madison, WI). 
TLR10 chimeric receptors and internal chimeras— TLR1-10, TLR10-1 and 
TLR10-6 were created by overlap extension PCR (Horton et al., 1990). TLR10 internal 
chimera T10 (6-17)/T1 and T10 (6-17)/T6 were generated using the unique TLR1 and 
TLR6 constructs made previously in which unique restriction sites were engineered at the 
end of LRR5 (Omueti et al., 2005). The LRR 6-17 region of TLR10 was amplified with 
appropriated enzyme sites at both ends and ligated into the digested products of TLR1 or 
TLR6. 
TLR-ECD-Fc Fusions--Pure soluble forms of TLR1, TLR2, and TLR10 were 
produced in large quantities using the hybrid LRR technique developed by Jin et al. (Kim 
et al., 2007). In short, a truncated portion of the TLR ectodomain lacking the C-terminal 
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cap was fused to the highly conserved LRR C-terminal capping module of VLRB.61, a 
hagfish variable lymphocyte receptor. With the aid of the computer software 
DNAWorks(Bethesda, MD) (Hoover and Lubkowski, 2002), six adjacent sets of ~60-bp 
overlapping oligonucleotides were used to synthesize the sequence encoding amino acids 
133-200 of the hagfish VLRB.61 clone (amino acid 133-200). Using overlap extension 
PCR, the VLR coding region was fused to the 3’-end of TLR 1, 2, and 10 ECD 
encompassing amino acids 22-476, 17-508, and 20-474, respectively. The PCR products 
were cloned as a BglII/NheI fragment into a modified pDisplay vector containing an HA-
tag upstream of the BglII site and an Fc domain of the human IgG1 downstream of the 
NheI site (kindly provided by Dr. David M. Kranz, Department of Biochemistry, 
University of Illinois at Urbana-Champaign). A thrombin cleavage site (LVPRGS) was 
also added at the 3’-end of the TLRvlr hybrid to allow cleavage of the soluble TLR from 
the Fc fusion protein. A Flag-tagged TLR2vlr-Fc construct was also engineered. (The 
constructs of TLR-ECD-Fc Fusions were generated by another graduate student, Diana 
Rose Ranoa, in the Tapping laboratory.) 
TLR10 mutants— Site-directed mutagenesis of the TLR10 mutants was 
performed in TLR10 chimeric receptor TLR10-1. Oligos encoding amino acid changes 
were designed and used to introduce mutations into the TLR10 template through PCR.  
TLR Retroviral vectors—The retrovirus vector pMXs-IRES-GFP (Cell Biolabs, 
San Diego, CA) was modified by inserting the preprotyrpsin signal sequence followed by 
a FLAG linker into BamH1 and Not1 site to generate pMX-preprotrypsin-FLAG plasmid. 
The coding sequences of TLR1, TLR10 and TLR10-1 were directly inserted into the 
modified retrovirus vector to generate pMX-TLR1, pMX-TLR10 and pMX-TLR10-1. 
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(The constructs of TLR Retroviral vectors were generated by a post-doctoral researcher, 
Xinyan Li, in the Tapping laboratory.) 
Cell culture and stable cell lines- The human colonic epithelial cell line SW620 
was cultured in RPMI 1640 media containing 10%(v/v) fetal bovine serum (FBS) and 
2mM L-glutamine. 293T cells were cultured in DMEM medium supplemented with 
10%(v/v) FBS, 2mM L-glutamine. The human TLR10 expressing, stable RAW 264.7 cell 
lines were obtained by nucleofection (Lonza, Basel, Swizerland) of HA-tagged TLR10 
plasmid or an empty vector control into RAW 264.7 cells. After selecting in G418 (0.3 
mg/ml) for 3 weeks, stable batch cell lines expressing high level of TLR10 were verified 
by both RT-PCR and flow cytometry using anti-HA antibody. Cells were cultured at 
37°C in a humidified environment containing 5% CO2. (Stable RAW 264.7 cell lines 
were generated by another graduate student, Song Jiang, in the Tapping Laboratory.) 
Stable HEK 293F cell lines expressing recombinant soluble forms of each TLR 
ECD-Fc fusion protein were generated by transfection of the recombinant TLR plasmids 
using the cationic lipid transfection reagent, 293fectinTM (Invitrogen Life Technologies). 
Cells were then cultured under G418 selection (0.25 mg/ml) for 3-4 weeks, and 
individual stable clones expressing high levels of recombinant TLR protein were isolated 
using limiting dilution cloning and selected by western blotting. Clones were cultured at 
37oC, 8% CO2 in serum-free Freestyle 293F expression medium (Invitrogen Life 
Technologies). (Stable HEK 293F cell lines were generated by another graduate student, 
Diana Rose Ranoa, in the Tapping Laboratory.) 
Transient transfection and dual luciferase reporters assay- SW620 cells or 293T 
cells were cotransfected with various TLRs combinations along with an experimental 
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promoter driven firefly luciferase reporter and a Renilla luciferase transfection control 
reporter (pRL-Null). Transfection was mediated by using Fugene6 (Roche Applied 
Science, Indianapolis, IN) at a lipid to DNA ratio of 4:1. Two days after transfection, 
cells were stimulated with indicated agonists for at least 6 hours and cell lysates were 
collected. Luciferase enzyme activities were measured using Dural-luciferase reporter 
assay system (Promega). The values of firefly luciferase were first divided by those of 
Renilla luciferase values to normalize the transfection efficiency among different wells. 
Preparation of MEFs and Retroviral transduction- TLR1 deficient mice were a 
kind gift of Dr. Shizou Akira (Osaka University, Osaka, Japan). Murine embryonic 
fibroblasts (MEFs) were prepared from 13.5-day-old embryos and cultured in DMEM 
supplemented with 10% fetal bovine serum. Cells at passage 3, 4 or 5 were utilized for 
the experiments. For retrovirus infection, the 293T Ampho packaging cell line was 
transfected with retroviral vectors using Fugene 6 reagent (Roche Applied Science). The 
viral supernatant was harvested 48 hours post transfection and used to infect MEF cells 
by incubating with MEFs cells under 10ug/ml polybrene (Sigma-Aldrich) for 24 hours. 
After culturing cells in fresh DMEM medium for another 24 hours, the infected MEFs 
were collected and plated in 96-well plate at the density of 1x104 cells per well and 
cultured for 12 hours. For stimulation, cells were treated with increasing concentrations 
of Pam3CSK4 for 24 hours. The concentration of mouse IL-6 in the culture supernatant 
was measured by ELISA using paired antibodies (Invitrogen). (This work was performed 
by a post-doctoral researcher, Xinyan Li, in the Tapping laboratory.) 
Confocal Microscopy- Stable cell lines of RAW 264.7 cells expressing HA-
tagged TLR10 were grown on chambered microscope slides (Lab-Tek, Nalge Nunc, 
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Rochester, NY) and incubated with 2x106 zymosan particles/ml for 10 minutes. Cells 
were fixed in 4% paraformaldehyde for 20 min and permeabilized in acetone for 5 
minutes at -20°C.  Non-specific sites were then blocked by incubating for 30 minutes at 
4°C in blocking buffer (PBS/10% rabbit serum/0.03% NaN3).  HA-tagged TLR10 was 
detected by using mouse anti-HA monoclonal antibody (Sigma-Aldrich), biotin-
conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories), and 
Streptavidin conjugated Alexa 555 (Molecular Probes, Eugene, OR).  Cells were then co-
stained for mouse TLR2 using a directly conjugated TLR2.5-Alexa 488 antibody 
(eBioscience). All images were obtained with 40X objective and oil immersion using a 
Zeiss LSM510 (Carl Zeiss, Thornwood, NY) confocal microscope at the School of 
Molecular and Cellular Biology Imaging Facility (University of Illinois, Urbana, IL). 
Vector control cell lines did not exhibit staining for the HA tag. (This work was 
performed by another graduate student, Jiang Song, in the Tapping laboratory.) 
Immunoprecipitation and Western Blot- HEK 293T cells were transfected in 10-
cm tissue culture dishes with specific TLRs along with MyD88 (0.75 ug of HA-tagged 
TLR2, 2.25 ug of FLAG-tagged TLR1 or TLR10, 1 ug of FLAG-tagged MyD88). 24 
hours post transfection, half the dishes were treated with Pam3CSK4 (200ng/ml) for 
10min and all cells were lysed using RIPA buffer. Cell extracts were incubated with anti-
HA affinity gel for 1 hour at 4 °C followed by extensive washes of the beads with lysis 
buffer. Samples were separated on 7.5% PAGE and transferred to Hybond-P membrane 
(GE healthcare, Piscataway, NJ). Western blotting was performed using HRP-conjugated 
anti-FLAG antibody (M2) or HRP-conjugated anti-HA antibody. 
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Protein purification- 293F cell lines stably expressing TLR-ECD-Fc fusion 
proteins were seeded at 0.3x106 cells/ml in serum-free medium and incubated with 
shaking for 5 days. Recombinant protein G sepharose beads (GE Healthcare; 1ml 50% 
slurry) were added to 1L of filtered culture supernatants, and stirred at 4oC overnight. 
Protein G beads were recovered by centrifugation at 3000xg for 15 minutes at 4oC and 
subsequently packed in a glass column connected to the AKTA prime purification system 
(GE Healthcare). The beads were washed with 30 ml binding buffer (20mM sodium 
phosphate buffer pH 7.0) at a flow rate of 1.0 ml/min, and the fusion protein was eluted 
with 0.1M glycine-chloride (pH 2.3) in 1.0-ml fractions into tubes containing 100ul of 
neutralizing buffer Tris-Cl (pH 9.0). The eluted protein was dialyzed overnight against 
PBS (pH 7.4) at 4oC. Proteins were concentrated using Amicon ultra centrifugal filter 
device with 10,000 nominal molecular weight limit (Millipore, Bedford, MA). The 
protein concentration was measured using bicinchoninic acid assay (BCA).  
The TLRvlr-Fc fusion protein was then incubated with thrombin (Novagen, 
Gibbstown, NJ) at 25oC for 16-18 hours to facilitate the removal of the Fc tag, at an 
optimized concentration of 1U thrombin per 0.25 mg fusion protein. After thrombin 
cleavage, protein G beads were added to the protein samples to remove Fc fragments as 
well as uncut Fc-tagged TLRvlr in solution. After 2 hours incubation at 4oC, the slurry 
was passed through a spin filter (Novagen) to separate the beads containing Fc fragments 
and uncut proteins from the TLRvlr proteins. The purity of the hybrid proteins was 
determined by mass spectrometry (Mass Spectrometry Laboratory, School of Chemical 
Sciences, University of Illinois at Urbana-Champaign) using MALDI as ionization 
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technique and sinapinic acid as a calibration matrix. Final protein concentration after 
thrombin cleavage was measured using the BCA assay.  
Receptor-binding assays- HA-tagged TLR1vlr and TLR10vlr hybrid proteins 
(10μg/mL in PBS pH 7.4) were coated in microtiter wells overnight at 4oC. For all 
ELISAs binding steps were performed at room temperature in MES buffer (pH 7.5) and 
wells were washed with PBS containing 0.05% Tween-20. After blocking with a 
commercially-available blocking buffer (Pierce, Rockford, IL) for 2 hours, wells were 
washed and incubated with an equimolar amount of Flag-tagged TLR2vlr that had been 
pre-incubated for 2 hours at 25oC with various concentrations of the synthetic ligand 
Pam3CSK4, MALP-2, and Ac2CSK4, in MES buffer (pH 7.5). One set of preincubation 
reactions contained 20μg/ml blocking anti-TLR2 antibody (T2.5). After washing, wells 
were incubated with HRP-conjugated anti-Flag (M2) mAb (Sigma-Aldrich). Detection 
was performed by the addition of o-phenylenediamine (OPD) tablet (Sigma-Aldrich) 
dissolved in 0.05M Phosphate-citrate buffer (pH 5.0) containing 0.05% H2O2. The 
colorimetric signal was stopped with 4N H2SO4 and absorbance at 490nm was read using 
an ELISA plate reader. (This work and protein purification was performed by another 
graduate student, Diana Rose Ranoa, in the Tapping laboratory.)  
Modeling of the TLR2/10/lipopeptide complex- The program MOE version 2006 
(Chemical Computing Group, Montreal, Quebec, Canada) was used for all the modeling 
work. The amino acid sequence of the TLR1 ECD was aligned with the sequence of the 
TLR1 sequence as in the TLR10/TLR2/lipopetide complex (NCBI Protein Databank 
entry 2Z7X (Jin et al., 2007)), using the BLOSUM62 scoring matrix as implemented in 
MOE, and 10 models were generated using the HOMOLOGY function provided in the 
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MOE program. Each of these 10 models was submitted to an energy minimization using 
the CHARMM force field (Brooks et al., 2009) version 27 as implemented with MOE, 
with solvent effect implicitly described using distance-dependant dielectric and a cutoff 
for non-bonded interactions between 8 Å and 10 Å. During the homology modeling, the 
structure of TLR10 was modeled with the explicit inclusion of TLR2 and lipopeptide 
structures. 
Results 
TLR10 signaling is distinct from that of other TLR2 subfamily members- All 
TLRs are characterized by an N-terminal extracellular domain (ECD), comprised of 
leucine rich repeat motifs (LRRs), followed by a single spanning transmembrane domain 
(TM) and a C-terminal intracellular Toll/Interleukin-1 receptor (TIR) signaling domain. 
To assess the function of TLR10 without knowledge of the ligand, the ECD domain of 
the receptor was replaced with that of CD4; an approach that has previously been used to 
generate constitutively active forms of the TLRs (Medzhitov et al., 1997; Ozinsky et al., 
2000). Following transfection, a CD4-TLR10 fusion failed to induce reporter gene 
expression from a variety of promoters including NF-κB, IL-8, and IFN-β (Fig. 3.1). In 
contrast, a CD4-TLR4 positive control activated expression of all of these reporter 
constructs. Since TLR10 is most highly related to TLRs 1 and 6, I hypothesized that, 
similar to these receptors, it may be a heterodimeric partner for TLR2. As expected, 
cotransfection of CD4-TLR1 and CD4-TLR2 induced activation of NF-κB and IL-8-
driven luciferase reporters. In contrast, CD4-TLR10 in combination with CD4-TLR2 
failed to activate any of the reporters (Fig. 3.1). Notably, cell surface expression of all the 
CD4-TLR chimeras was confirmed (Appendix Fig. A.1). Taken together, these results 
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suggest that CD4-TLR10, either alone or in combination with TLR2, fails to activate 
reporters commonly associated with TLR signaling. 
TLR10 is a partner for TLR2 and shares a variety of agonists with TLR1- TLR1 
and TLR6 enable TLR2 to discriminate between different microbial products including 
bacterial lipoproteins (Takeuchi et al., 2001; Takeuchi et al., 2002). For instance, the 
TLR2/1 dimer mediates responses to the triacylated lipopeptide Pam3CSK4, whereas the 
TLR2/6 dimer is required for detection of diacylated lipopeptides such as MALP-2. 
Functional analyses demonstrated that the receptor ECD is responsible for lipopeptide 
recognition and structural studies showed that the Pam3CSK4 ligand is coordinately 
bound by TLR1 and TLR2 (Jin et al., 2007; Omueti et al., 2005; Sandor et al., 2003). 
Given the phylogenetic relationship between TLRs 1, 6 and 10, I hypothesized that 
lipopeptides could also be agonists for the latter receptor. To investigate this hypothesis 
chimeric receptors were generated in which the ECD and TM domains of human TLR10 
and TLR1 were swapped (Fig. 3.2A). After confirming the expression of the chimeric 
receptors on the cell surface (Appendix Fig. A.2), I assessed their ability to mediate 
cellular responses to lipopeptides using SW620 cells, a human epithelial cell line in 
which the activities of TLR2 subfamily members can be reconstituted due to lack of 
endogenous expression (Omueti et al., 2005). As expected, TLR1 enabled cells co-
expressing TLR2 to respond to Pam3CSK4 (Fig. 3.2B). However, neither TLR10 nor the 
reciprocal TLR1-10 chimera, comprising the TLR1 ECD and TM domain fused to 
TLR10 signaling domain, could reconstitute lipopeptide responses when co-expressed 
with TLR2 (Fig. 3.2B). Importantly, TLR10-1, a chimeric receptor in which the ECD and 
TM domain of TLR1 was replaced with that of TLR10, mediated full responses to 
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Pam3CSK4 in cooperation with TLR2. Taken together, these results demonstrate that 
TLR10 cooperates with TLR2 in sensing of triacylated lipopeptides. The lack of response 
of TLR10/2 to Pam3CSK4 supports the idea that signaling from this receptor complex 
differs from that of related family members. 
To fully confirm the role of TLR10 in sensing microbial lipopeptides, 
reconstitution experiments were performed using mouse embryonic fibroblasts (MEFs) 
derived from TLR1-deficient animals. The TLR1 deficient MEFs were transduced with 
retroviral vectors expressing human TLR1, TLR10-1, and wild type TLR10 and then 
cultured in the presence of varying concentrations of Pam3CSK4 (Fig. 3.2C). As reported 
previously, TLR1-deficient cells exhibit very weak responses to Pam3CSK4 (Takeuchi et 
al., 2002). As expected, retroviral expression of hTLR1 enabled higher sensitivity and 
robust responses of MEFs to Pam3CSK4. Importantly, TLR1 deficient MEFs 
reconstituted with chimeric TLR10-1 receptor also exhibited sensitivity and responses to 
Pam3CSK4 comparable to that of TLR1 transduced cells. These results demonstrate that 
chimeric TLR10-1 rescues the responses of TLR1 deficient cells to triacylated 
lipopeptides. Interestingly, production of IL-6 in TLR1 deficient MEFs transduced with 
virus expressing wild type TLR10 exhibited slightly enhanced dose-dependent responses 
to Pam3CSK4 compared to empty virus, suggesting that the cytoplasmic domain of 
TLR10 may weakly activate IL-6 production in these cells. 
To better define the agonist specificity of TLR10, cells coexpressing TLR10-1 
and TLR2 were stimulated with synthetic lipopeptide compounds and a variety of natural 
microbial agonists with differing specificity toward TLR1/2 or TLR2/6. PamCysPamSK4 
and PamCSK4 are TLR2/1 specific agonists that are missing either one or both lipids of 
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the diacyl glycerol group of Pam3CSK4 respectively (Omueti et al., 2005). In contrast, 
MALP-2 is a TLR2/6 specific agonist that possesses the diacyl glycerol group but lacks 
the third acyl chain on the N-terminal cysteine residue. In combination with TLR2, 
TLR10-1 mediated responses to TLR1-specific, but not TLR6-specific, synthetic 
lipopeptides (Fig. 3.3A). Similarly, cellular responses to zymosan, atypical LPS and heat-
killed microbes were mediated by TLR2 in combination with either TLR1 or TLR10-1. 
In contrast, cellular responses to lipoteichoic acid were instead enabled by TLR2 and 
TLR6, established receptor pairs for this agonist (Fig. 3.3B). Taken together, the data 
indicate that TLR10, coupled with TLR2, is able to detect a variety of microbial 
components and suggest that TLR10 shares agonist specificity with TLR1 but not with 
TLR6. A TLR10-6 chimeric receptor yielded results identical to those obtained with 
TLR10-1 supporting the idea that agonist specificity is dictated by the extracellular 
domains of the receptors (data not shown). Co-expression of wild type TLR10 with TLR2 
did not reconstitute responses to any of the TLR2 agonists, further suggesting a unique 
signaling function for this receptor complex. 
TLR2 and TLR10 physically interact and colocalize in phagosomes- TLRs 1, 2 
and 6 are recruited to phagosomes where they sense and mediate phagocyte responses to 
incoming microbial cargo (Ozinsky et al., 2000; Underhill et al., 1999). To examine 
TLR10 trafficking during phagocytosis, HA-tagged human TLR10 was stably expressed 
in the mouse macrophage cell line RAW264.7. In the absence of the stimulus, TLR10 
and TLR2 appear to be dispersed on the plasma membrane (Fig. 3.4). Upon incubation 
with zymosan particles both receptors are highly enriched and colocalize in early 
phagosomes. These results support the findings that TLR2 and 10 cooperate in mediating 
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responses to zymosan and show that both receptors localize to the phagosome during 
ingestion of whole microbes. 
To determine if TLR2 and TLR10 physically interact, co-immunoprecipitation 
studies were performed using HEK cells transiently expressing affinity tagged versions of 
different TLR pairs. TLR10 was observed to co-immunoprecipitate with TLR2 and this 
apparent association between the receptors increased with the addition of Pam3CSK4 
ligand (Fig. 3.5). As expected, a similar ligand-enhanced association was observed 
between TLR2 and TLR1 (Jiang et al., 2006; Johnson et al., 2007; Tapping and Tobias, 
2003). In addition, the recruitment of the proximal signaling adaptor MyD88 to the 
receptor complexes was assessed in these experiments. The co-immunoprecipitation of 
MyD88 with TLR2 alone was barely detectable and was greatly enhanced by co-
expression of either TLR1 or TLR10 in HEK cells (Fig. 3.5). The addition of Pam3CSK4 
ligand greatly enhanced the apparent recruitment of MyD88 to either TLR2/1 or TLR 
2/10 heterodimers. These results suggest that similar to TLR2/1 and TLR2/6 
heterodimers, TLR2/10 signaling involves the recruitment of MyD88 to the activated 
receptor complex. 
To further investigate ligand-induced physical interactions between TLRs, soluble 
forms of TLRs 1, 2 and 10 were produced using a hybrid LRR technique in which the 
ECD of each TLR was fused to a C-terminal LRR motif from hagfish (Jin et al., 2007). 
The physical association of purified TLR2 with TLR10 ECDs was studied using 
microtiter plate assays where TLR10 was immobilized on the plate followed by the 
addition of TLR2 alone or with various ligands. As shown in Fig.3.6A, TLR2 exhibited 
weak interaction with TLR10 which was greatly enhanced by the addition of Pam3CSK4 
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in a dose dependent fashion. Addition of an antagonistic anti-TLR2 antibody T2.5 (Meng 
et al., 2004) dose-dependently inhibited ligand-induced complex formation between 
TLR2 and TLR10. In contrast, the non-stimulatory control compound Ac2CSK4, lacking 
both the acyl- and amide-bound long chain fatty acids of Pam3CSK4, did not enhance 
physical association between TLR2 and TLR10 showing the requirement of lipid chains 
in formation of a stable heterodimer. Moreover, incubation with MALP-2, the diacylated 
lipopeptide agonist for TLR2/6, had no ability to induce a TLR2/10 complex. 
Collectively, these results demonstrated that the ECDs of TLR2 and TLR10 associate 
with each other to form a stable complex in a ligand-dependent manner. As expected, 
identical results were obtained using TLR1 as a control in place of TLR10 (Fig. 3.6B). 
Modeling of the TLR2/10/lipopeptide complex reveals structural similarity to the 
TLR2/1/lipopeptide complex- Similar to TLR1 and TLR6, the ECD of TLR10 is 
comprised of 19 sequential LRR motifs. Structurally, LRRs form a solenoid or spring in 
which each LRR motif comprises a single turn with the leucines, or other appropriately 
spaced hydrophobic residues, packed within the interior (Bella et al., 2008; Jin and Lee, 
2008). The solved crystal structure of the TLR2/1/lipopeptide complex reveals that the 
TLR2 and TLR1 solenoids form a heterodimer in which the lipid chains of Pam3CSK4 are 
coordinately bound (Jin et al., 2007). Two acyl chains of the diacyl glycerol group are 
accommodated by a hydrophobic pocket of TLR2 and the third amide-linked lipid chain 
occupies a hydrophobic channel in TLR1. The heterodimer is further stabilized by 
additional interactions at the dimer interface (Jin et al., 2007). Since TLR1 and TLR10 
share 43% amino acid identity at the ECDs, identical lipopeptide specificity, and TLR2 
as a coreceptor, computational modeling was deemed to be a reasonable approach for 
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gaining insights into the structure of the TLR2/10/lipopeptide complex. The 
computational model of TLR2/10/lipopeptide exhibits the same overall structure as that 
of the TLR1 containing complex (Fig. 3.7A). Similar to TLR1, the model predicts a 
hydrophobic channel on the convex surface of TLR10 which accommodates the amide-
linked lipid chain of the Pam3CSK4 lipopeptide. 
Prior to the solution of the TLR2/1/lipopeptide structure, domain swapping 
experiments between TLR1 and TLR6 successfully defined the central LRRs of these 
receptors as the region required for lipoprotein discrimination (Grabiec et al., 2004; 
Omueti et al., 2005). Since the ligand-binding and receptor dimerization region are 
predicted by the model to comprise the central LRRs of TLR10, the effects of exchanging 
LRRs 6-17 of TLR1 and TLR6 with that of TLR10 was examined as a first approach for 
validating the model and defining the region of the ECD required for lipopeptide 
recognition. As before, the ability of the chimeric receptors, in collaboration with TLR2, 
to mediate responses to different lipopeptides was assessed in SW620 cells (Fig. 3.7B). 
As observed previously, in conjunction with TLR2, TLR1 and TLR10-1 enabled cellular 
responses to Pam3CSK4, but not to MALP-2, whose activity was dependent upon TLR6. 
When LRRs 6-17 of TLR1 were replaced with the corresponding region of TLR10, 
T10(6-17)/T1), the receptor retained lipopeptide specificity. Additionally, when LRRs 6-
17 of TLR6 were replaced with those from TLR10, the resulting chimeric receptor, 
T10(6-17)/T6, exhibited full activity toward Pam3CSK4, but complete loss of activity 
toward MALP-2. These results demonstrate that LRRs 6-17 of TLR10 are responsible for 
defining the lipopeptide specificity of the receptor and support the molecular model of 
the TLR2/10/lipopeptide complex. 
68 
 
TLR10 and TLR1 interactions with TLR2 are similar but not identical- The 
residues which contribute to the formation of the binding pocket are conserved between 
TLR1 and TLR10 and preserve the overall shape of the lipid-binding channel (Fig. 3.8A 
and 3.8B). Hydrogen bonds between the peptide portion of Pam3CSK4 and TLR1 are also 
conserved in the TLR10 model (Fig. 3.8B). To further validate and explore the structural 
model, site-directed mutagenesis was performed on the residues in the ECD that appear 
to be crucial for ligand binding and TLR2 dimer formation. All of the receptor mutants 
were expressed on the cell surface (Appendix Fig. A.3) and their ability to mediate 
cellular responses to Pam3CSK4 were assessed. To provide a functional readout in the 
SW620 epithelial cell system, the TLR10 mutants were generated within the TLR10-1 
chimeric receptor. Corresponding amino acid residues in TLR1 were also assessed for 
comparative purposes. The model predicts that similar to TLR1, a loop comprising amino 
acids 311 to 316 contributes to the dimer interface and the entrance of the hydrophobic 
lipid binding channel (Fig. 3.8B and 3.8C). The orientation of the loop is important 
especially as the backbone oxygen between amino acids 313 and 314 forms a hydrogen 
bond with the lipoprotein (Fig. 3.8B). Phe314 of TLR1 and Ile314 of TLR10 are buried 
and make hydrophobic intramolecular contacts that appear to orient the protein backbone 
of the loop. Substitution with a charged lysine residue at position 314 almost completely 
abrogated the function of both receptors (Fig. 3.9A and 3.9B). In both TLR1 and TLR10, 
Val311 and Phe312 are positioned at the entrance of the channel; however substitution of 
either amino acid with a charged residue had little effect on the activity of either receptor 
to Pam3CSK4. Nearly complete loss of activity was observed following mutation of 
Gln316 whose side chain in both receptors forms a hydrogen bond with the amide oxygen 
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of the Pam3CSK4 lipid chain. The structural requirements for recognition of 
PamCysPamCSK4 by either TLR1 or TLR10 is identical to that of Pam3CSK4 and as 
expected, the various TLR1 and TLR10 mutants exhibit indistinguishable responses to 
these two ligands (Fig. 3.9A and 3.9B). 
Both TLR1 and TLR10 possess an extensive TLR2 binding interface comprised 
of a hydrophobic core surrounded by hydrogen bonding and ionic interaction networks 
(Jin et al., 2007) (Fig. 3.8C). In both receptor complexes, the hydrophobic core overlaps 
with the entrance of the lipid binding channel, however the surrounding polar and 
charged residues that make H-bonds and ionic interactions with TLR2 are less conserved 
between TLR1 and TLR10 (Fig. 3.8C). Hydrophobic interactions with TLR2 contributed 
by Pro315, Tyr320, Val339 and Leu359 of TLR1 are contributed by Leu342, Tyr320, 
Pro339, and Ile359 of TLR10, respectively (Fig. 3.8C). Substitution of either Tyr320, 
Pro339 or Ile359 with polar or changed amino acids dramatically reduced TLR10 activity 
towards Pam3CSK4 (Fig. 3.9A). Similarly, a Val339 mutant of TLR1 also exhibited 
greatly attenuated activity. In contrast to TLR10, the Tyr320 mutant of TLR1 retained 
most of the receptor activity. This residue is predicted by the model to make more 
intimate contact than TLR1 with the hydrophobic face of TLR2. Pro315 resides at the 
center of the hydrophobic core of TLR1 and interacts with Tyr323 of TLR2 (Fig. 3.8C). 
Substitution of Pro315 with leucine, which constitutes a naturally occurring polymorphic 
variant of TLR1, greatly attenuates receptor activity as reported previously (Omueti et al., 
2007). Conversely, substitution of Glu315 of TLR10 with leucine, which is not predicted 
by the model to contribute to heterodimer formation, retained more than half of the 
receptor activity (Fig. 3.9). In conclusion, the structural model of the 
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TLR2/10/lipopeptide complex is consistent with and supported by the mutational studies. 
While strikingly similar in overall structure, the TLR1 and TLR10 containing complexes 
appear to possess subtle differences at the TLR2 dimer interface. 
Discussion 
TLRs play a central role in host defense by driving appropriate inflammatory and 
adaptive responses following infection. The early identification of microbial agonists for 
the TLRs was greatly facilitated by the systematic generation and phenotypic assessment 
of knock-out mice and provided the first insights into TLR function (Akira et al., 2006). 
However, this approach is not feasible for defining the function of TLR10 as multiple 
gaps and insertions have rendered the receptor a pseudogene in mice as evidenced by 
sequences from a number of inbred strains (Hasan et al., 2005). I have found that Mus 
caroli, which emerged approximately 4 million years ago and predates the Mus musculus 
group, also possesses a TLR10 pseudogene characterized by numerous gaps and 
insertions (data not shown). The absence of TLR10 in mice, coupled with a lack of 
understanding of TLR10 signaling, has precluded the identification of synthetic or natural 
agonists and have rendered this receptor the only remaining orphan human TLR. 
I have performed experiments using chimeric receptors to overcome these 
obstacles based upon phylogenetic evidence that TLR10 is most related to TLR1 and 
TLR6, both of which independently cooperate with TLR2 in the sensing of a variety of 
microbial and fungal components. Through this approach, I report that TLR10 shares a 
number of microbial agonists with TLR1, but not TLR6, and utilizes TLR2 as a co-
receptor. Notably, expression of a chimeric receptor, which replaces the TLR1 ECD with 
that of TLR10, fully reconstitutes responses of TLR1-deficient macrophages to 
71 
 
triacylated lipopeptide. TLR10 and TLR2 colocalize in the early phagosome and the 
ECDs of the two receptors physically interact in a ligand-dependent manner. A 
computational model of the TLR2/10/lipopeptide complex and mutagenesis studies 
reveal similarities, as well as some subtle differences, in the ligand binding and dimer 
interface in comparison with the TLR2/1/lipopeptide crystal structure. Both analyses 
have showed that the residues contributed to TLR2 dimer interaction are less conserved 
between TLR10 and TLR1. Therefore, it is not surprising that TLR10, in cooperation 
with TLR2, mediated limited responses to the novel synthetic TLR2/1 agonists 
discovered in Chapter Two.  These low-molecular-weight agonists are predicted to bind 
directly within the interface of the TLR2/1 dimer (see details in Chapter Two). Only at 
concentrations higher than 10 µM, compound A exhibited some activity toward 
TLR2/10-1, while its activation of TLR2/1 was detected at a concentration of 30 nM 
(Appendix Fig. A.4 and Fig. 2.2). Neither compound B nor compound C exhibited any 
ability to activate the cells expressing the TLR2 and TLR10-1 even at the highest 
concentration tested, indicating these compounds are TLR1 specific agonists and not 
sensed by TLR10. 
The idea that agonist recognition drives receptor dimer formation is supported by 
the finding that artificial chimeric receptors which replace the TLR ECD with either CD4 
or integrin pairs, that form natural dimers, exhibit constitutive activation (Medzhitov et 
al., 1997; Ozinsky et al., 2000; Zhang et al., 2002). I have found that expression of CD4-
TLR10, either alone or with CD4-TLR2, was unable to activate NF-κB, IL-4, IL-8, ENA-
78 or IFN-β driven promoters in HEK293 or SW620 cells (Fig. 3.1 and data not shown). 
These findings are in contrast to a report showing that CD4-TLR10 activated NF-κB, IL-
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4 and ENA-78 driven promoters in HEK cells (Hasan et al., 2005). Despite the ability to 
appropriately activate these promoters using either CD4-TLR4 or a combination of CD4-
TLR1 and CD4-TLR2, I have been unable to detect TLR10-dependent activation of any 
of the reporter constructs (Fig. 3.1). In support of this work, an integrin-TLR10 chimera, 
either alone or with an appropriate integrin-TLR2 partner, does not activate NF-κB 
despite the fact that other integrin-TLR combinations are able to do so (Zhang et al., 
2002).  In addition, I found that either TLR1, TLR6 or TLR10-1, but not TLR10, induces 
NF-κB or IL-8 driven promoters in response to lipopeptide when coexpressed with TLR2 
(Fig. 3.2). 
TLR signaling is mediated by an intracellular Toll/IL-1 receptor (TIR) domain, so 
named because it shares homology with that of IL-1 receptor (O'Neill and Bowie, 2007; 
West et al., 2006). The appropriate association of two intracellular receptor TIR domains 
enables the recruitment of specific TIR domain-containing adaptor molecules which 
ultimately induce the expression of appropriate immune response genes (Kawai and 
Akira, 2007; O'Neill and Bowie, 2007; Sheedy and O'Neill, 2007; West et al., 2006). The 
crystal structures of the solved TIR domains of TLR1, TLR2 and TLR10 exhibit a 
conserved fold composed of five parallel β-sheets surrounded by five α-helical segments 
(Nyman et al., 2008; Xu et al., 2000). Multiple studies have shown that 2 exposed 
segments, designated the BB loop and the DD loop, are critical for dimer formation and 
adaptor recruitment which drive downstream signaling (Gautam et al., 2006; Poltorak et 
al., 1998; Toshchakov et al., 2005; Xu et al., 2000).  The TLR10 TIR domain crystallizes 
as a dimer with juxtaposed BB loops (Nyman et al., 2008), however the idea that this 
constitutes a physiologically relevant form of the receptor is based upon receptor activity 
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experiments that I cannot reproduce (Hasan et al., 2005). Instead of BB loop interactions, 
rigid body protein-protein docking studies between the TIR domains of TLR1 and TLR2 
reveal a different orientation which involves an interaction between the BB loop of one 
monomer and the DD loop of another (Gautam et al., 2006). In this configuration His646, 
Asn700, Gly676 and Tyr737, which are perfectly conserved between TLR1 and TLR10, 
comprise the TIR domain dimer interface with TLR2 (Gautam et al., 2006).  
Despite conservation, there are substantial sequence differences between TIR 
domains of TLR10 and TLR1. Most notably, TLR1 and TLR6 have identical RNFVPG 
BB loop sequences while that of TLR10 consists of SYFDPG and also includes a two 
amino acid insertion in the preceding α-helix. These and other differences within the 
TLR10 signaling domain may contribute to a distinct charge distribution in TLR2/10 
surface that confers a unique specificity for adapter binding and downstream signaling 
(Dunne et al., 2003). I have observed that the adaptor MyD88 co-immunoprecipitates 
with the TLR2/10 heterodimer and that this interaction is enhanced by lipopeptide agonist 
(Fig. 3.5). However, TLR2/10 fails to activate signals typically associated with MyD88 
activity, including canonical activation of NF-kB, suggesting that recruitment of this 
adaptor to TLR2/10 is distinct from that of other TLRs including the closely related 
TLR2/1 and TLR2/6 heterodimers. The idea that recruitment of MyD88 can differ among 
TLR2 heterodimers is not without precedence as an I179N point mutation in this adaptor 
abolishes MyD88-dependent signaling of all TLR complexes, including TLR2/1, while 
having no effect on MyD88-dependent TLR2/6 signaling (Jiang et al., 2006). 
In addition to phylogenetic evidence, the unique expression pattern of TLR10 
further suggests a functional divergence from TLR1 and TLR6. In comparison to these 
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latter two receptors, TLR10 expression appears to be more restricted with RNA message 
found predominantly in lymphoid tissues including the spleen, lymph nodes, thymus and 
tonsils (Chuang and Ulevitch, 2001; Opsal et al., 2006; Shinkai et al., 2006). An analysis 
of isolated cell types reveals that high levels of TLR10 expression are restricted to the B 
cell lineage with weaker expression in plasmacytoid dendritic cells (Bourke et al., 2003; 
Hasan et al., 2005; Hornung et al., 2002). While TLR expression levels are generally low 
in naïve B cells, they are highly induced upon BCR stimulation (Bernasconi et al., 2003; 
Bourke et al., 2003). A variety of TLR agonists have been shown to act directly on B 
cells to induce antibody production to T-independent antigens (Vasilevsky et al., 2008) 
and to enhance proliferation, isotype switching and differentiation in response to T-
dependent antigens  (Meyer-Bahlburg et al., 2007; Pasare and Medzhitov, 2005; Ruprecht 
and Lanzavecchia, 2006). TLR7 and TLR9 agonists are generally the focus of many of 
these studies, especially given their potential utility as therapeutics (Kanzler et al., 2007) 
and their established role in the autoimmune condition lupus (Marshak-Rothstein, 2006). 
However, TLR2 agonists can also provide stimulatory signals to human B cells (Chiron 
et al., 2008; Ganley-Leal et al., 2006; Mansson et al., 2006). Memory B cells 
constitutively express a number of TLRs, including TLR2 and TLR10, and can be 
induced by TLR agonists to proliferate and differentiate to plasma cells (Bernasconi et al., 
2003; Bourke et al., 2003). Concordantly, cell lines derived from mature B cell 
neoplasias express high levels of TLR10 and a variety of TLR ligands, including 
lipopeptides, enhance the survival of both multiple myeloma and chronic lymphocytic 
leukemia cells (Bohnhorst et al., 2006; Bourke et al., 2003; Muzio et al., 2009).  
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In an analogous manner, TLRs have also been shown to play a direct 
costimulatory role during T cell activation (Marsland and Kopf, 2007). Human T cells 
express high levels of TLR2 following T cell engagement and these cells produce 
elevated levels of cytokine in response to lipopeptide (Komai-Koma et al., 2004). TLR2 
is constitutively expressed in memory T cells which exhibit enhanced responses to 
lipopeptides. Taken together with the observations in B cells, the results suggest that 
TLR10 plays an ancillary role in lymphocyte stimulation especially where the expansion 
and controlled maintenance of memory B and T cells are concerned. Further evidence 
that TLR10 plays a role in the control of adaptive immune responses is the finding that 
this receptor is expressed by regulatory T cells through transcription factors Foxp3 and 
NF-AT (Bell et al., 2007). It is worthy to note that TLR10 genetic variants have been 
associated with susceptibility to both extrapulmonary tuberculosis and to asthma (Lazarus 
et al., 2004; Ma et al., 2007), two diseases in which TLR2-mediated adaptive immunity is 
thought to play a major role. 
The discovery that TLR10 is orthologous to TLR1 in ligand recognition but not 
signaling calls for a re-evaluation of studies where lipoproteins or other TLR2/1 agonists 
have been used in the stimulation of human and other non-murine mammalian systems. 
In vivo, the competition of TLR1 and TLR10 for both ligand and coreceptors such as 
TLR2 is likely to have significant functional consequences given the different expression 
patterns and signaling outputs of these two receptor complexes. In addition to providing a 
means to study TLR10 function, the discovery of lipopeptides and other microbial 
agonists for this receptor has important implications for the future therapeutic targeting of 
TLR2. 
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Figures 
 
 
Figure 3.1. The TLR10 homodimer and TLR2/TLR10 heterodimer do not induce 
activation of NF-B, IL-8 and IFN- promoters. HEK 293 cells were cotransfected with 
indicated CD4-TLR constructs (400 ng/ml), various luciferase reporters (150 ng/ml) and 
a Renilla luciferase transfection control (50 ng/ml). Luciferase activities were measured 
48 hours post transfection. Values represent the level of constitutive reporter activation 
over that of vector alone whose activity was taken as one. The error bars represent the 
standard deviation of three independent values. 
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Figure 3.2. TLR10 cooperates with TLR2 and senses synthetic lipopeptides. (A) 
Schematic diagrams of wild type or TLR1 and TLR10 chimeric constructs. (B) SW620 
cells were cotransfected with the dimeric constructs (180ng/ml) along with TLR2 
(20ng/ml), an IL-8 driven luciferase reporter and a Renilla luciferase transfection control 
as indicated. Two days after transfection cells were stimulated for 6 hours with 20ng/ml 
Pam3CSK4 followed by measurement of luciferase activity. Values represent the level of 
reporter activation over that of vector alone whose activity was taken as one. (C) MEFs 
were derived from TLR1 knock-out mice and transduced with retroviruses encoding the 
indicated constructs. The cells were subsequently incubated with increasing 
concentrations of Pam3CSK4 for 12 hours and IL-6 concentrations in the culture 
supernatant were measured by ELISA. Error bars represent the standard deviation of 
three independent values. 
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Figure 3.3.  TLR10 shares agonist specificity with TLR1. SW620 cells were cotransfected 
with indicated combinations of TLRs, an IL-8 promoter driven luciferase reporter and 
Renilla transfection control reporter. Cells were stimulated for 6 hours with (A) 1µg/ml 
PamCSK4, 20ng/ml PamCysPamCSK4, 20ng/ml Malp-2, or (B) 107 particles/ml zymosan, 
2µg/ml LTA-SA, 20ng/ml P. gingivalis LPS (P.G. LPS),  200µg/ml heat-killed S. aureus 
(HKSA) or 107 particles/ml heat-killed A. laidlawii (HKAL) followed by luciferase 
activity assays. Values represent the level of reporter activation over that of vector alone 
whose activity was taken as one. Error bars represent the standard deviation of three 
independent values.  
 
 
79 
 
 
Figure 3.4. TLR2 and TLR10 co-localized in phagosomes. RAW 264.7 cells stably 
expressing HA-TLR10 were either untreated or incubated with zymosan particles at 
2x106/ml for 10 minutes before fixing. Cells were co-stained for endogenous TLR2 
(Alexa 488) and HA-tagged TLR10 (Alexa 555) followed by confocal fluorescence 
microscopy. 
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Figure 3.5. TLR10 interacts with TLR2 and the receptor complex recruits MyD88. HEK 
293T cells were co-transfected with indicated TLRs and FLAG-tagged MyD88. One day 
after transfection, cells were either untreated or treated with  Pam3CSK4 at 200ng/ml for 
10min. Cell lysates were immunoprecipitated with anti-HA antibody and samples were 
analyzed for the presence of TLR10, TLR1 and MyD88 using anti-FLAG antibody. 
Whole cell lysates (WCE) were analyzed to verify the expression of transfected TLRs 
and MyD88. 
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Figure 3.6. Binding of TLR2 to either TLR10 or TLR1 is induced by Pam3CSK4. (A) HA-
tagged TLR10 ECD or (B) HA-tagged TLR1 ECD was immobilized on microtiter wells, 
followed by incubation with Flag-tagged TLR2 with increasing concentrations of 
Pam3CSK4 with or without T2.5 Ab), MALP-2, or Ac2CSK4 as indicated. The amount of 
protein binding was detected through an HRP-conjugated anti-Flag antibody. Data are 
representative of a least three independent replicates.  
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Figure 3.7. Modeling of the TLR2/10/Pam3CSK4 complex and functional analyses of 
receptor chimeras reveal a role for the central LRRs of TLR10 in Pam3CSK4-mediated 
activation. (A) A computational model of TLR10 (yellow) in the complex with TLR2 
(blue) and Pam3CSK4 (red) based upon the crystal structure of the TLR2/1/lipopeptide 
complex. (B) SW620 cells were cotransfected with the indicated combinations of TLRs, 
an IL-8 promoter driven luciferase reporter and a Renilla luciferase control. Cells were 
stimulated with 20ng/ml Pam3CSK4 or 20ng/ml Malp-2 followed by measurement of 
luciferase activity. Values represent the level of reporter activation over that of vector 
alone whose activity was taken as one. Error bars represent the standard deviation of 
three independent values.  
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Figure 3.8. The predicted lipopeptide-binding sites and receptor dimer interface of 
TLR2/TLR10 complex. (A) Sequence alignment of LRRs 9 through 14 of TLR1 and 
TLR10. Consensus sequences are shown in red. The mutated sites in TLR1 or TLR10 are 
labeled with asterisks. (B) The modeled lipid-binding channel in TLR10 and the main 
dimerization interface between TLR10 and TLR2. The side chains of TLR10 residues 
(gold) that interact with residues in TLR2 (blue) are shown along with carbon (grey), 
nitrogen (blue), oxygen (red) and sulfur (yellow) atoms of the lipopeptide. Hydrogen 
bonds are depicted as straight pink lines. Lipopeptide elements are shown in gray 
(carbon), blue (nitrogen), red (oxygen) and yellow (sulfur). All three-dimensional 
illustrations were produced with UCSF Chimera (Pettersen et al., 2004) (C) Residues 
involved in the receptor dimer interface in TLR2/10/lipopeptide model or the 
TLR2/1/lipopeptide structure are shown and interactions are depicted by dotted lines (Jin 
et al., 2007).  
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Figure 3.9.  Mutation of TLR10 residues essential to TLR2/TLR10/lipopeptide complex 
formation affects receptor function. SW620 cells were cotransfected with TLR2, (A) 
various TLR10 mutants or (B) various TLR1 mutants as indicated along with an IL-8 
promoter driven luciferase reporter and Renilla luciferase control. Cells were stimulated 
with 20ng/ml Pam3CSK4 or 20ng/ml PamCysPamSK4 for 6 hours followed by luciferase 
activity assays. Results are presented as the percentage of the wild type receptor response 
and error bars represent the standard deviation of three independent values. 
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CHAPTER FOUR 
GENERATION OF MONOCLONAL ANTIBODIES AGAINST TOLL-LIKE 
RECEPTOR 10 AND CHARACTERIZATION OF THE RECEPTOR 
EXPRESSION PROFILE IN HUMAN BLOOD CELLS 
Introduction 
Among human TLRs, TLR10 is the only remaining family member without a 
defined function. Phylogenetic analysis has shown that TLR10 belongs to the TLR2 
subfamily which includes TLRs 1, 2, 6 and 10. TLR10 is most closely related to TLR1 
and TLR6 and these three genes share a tandem locus on chromosome 4p14 (Beutler and 
Rehli, 2002). TLR1 or TLR6 cooperates with TLR2 to function and the heterodimeric 
TLR2/TLR1 or TLR2/TLR6 complexes mediate responses to a great variety of agonists, 
including bacterial lipoproteins, lipoteichoic acid, zymosan from yeast cell walls, 
peptidoglycan of Gram-positive bacteria, atypical LPS derived from non-enteric bacteria, 
and membrane lipoarabinomannans from mycobacteria. (Akira et al., 2006; Takeda et al., 
2003). Cooperation with either TLR1 or TLR6 enables TLR2 to discriminate the subtle 
differences between tri- and di- acylated lipopeptides. TLR2/1 recognizes triacylated 
Pam3CSK4, while TLR2/6 responds to diacylated MALP-2. Crystal structure studies have 
revealed that ligand recognition involves direct contact of the lipopeptide with both 
receptors in the heterodimer (Jin et al., 2007; Kang et al., 2009). In Chapter Three, I 
reported that TLR10 also cooperates with TLR2 in the recognition of triacylated 
lipopeptides and other microbial-derived agonists shared by TLR1. The structural model 
of TLR2/TLR10/lipopeptide predicted the presence of a lipid-binding channel in TLR10. 
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However, TLR10 failed to activate the signaling typically associated with other TLR2 
family members (Guan et al., 2010). 
Members of the TLR family are differentially expressed on leukocytes and 
endothelial cells. In general, monocytes/macrophages and dendritc cells express most 
TLR subsets (Kadowaki et al., 2001; Muzio et al., 2000; Zarember and Godowski, 2002). 
The characterization of TLR expression in various tissues and cell types is crucial to 
understanding TLR function. Previous studies have shown that the presence of TLR10 
mRNA is more tissue- and cell- type specific than that of TLR1 and TLR6, an indication 
of its functional divergence from the latter two receptors. The mRNA of TLR10 is highly 
expressed in lymphoid tissues such as spleen, lymph nodes, thymus and tonsils (Chuang 
and Ulevitch, 2001).  Analyses of isolated cell types demonstrated that TLR10 transcripts 
are specifically limited to B cell lineages and are weakly expressed in plasmacytoid 
dendritic cells (pDC) (Bourke et al., 2003; Hasan et al., 2005; Hornung et al., 2002). 
Moreover, the expression level of TLR10 is dramatically up-regulated by activation of 
resting B cells (Bourke et al., 2003). TLRs expressed in B cells have been shown to be 
involved in proliferation, differentiation and production of specific antibodies in response 
to TLR agonists (Lanzavecchia and Sallusto, 2007; Pasare and Medzhitov, 2005). For 
example, naïve B cells respond to lipopeptides and CpG DNA (a TLR9 ligand), with 
enhanced cell proliferation, differentiation and IgM secretion (Ganley-Leal et al., 2006; 
Ruprecht and Lanzavecchia, 2006).  pDCs, also known as interferon-producing cells, are 
a subset of dendritic cells with B cell morphology. pDCs are specialized in producing 
large amounts of type I interferons, particularly IFN-α, upon stimulation with viral 
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nucleic acid-containing complexes recognized by TLR7 and TLR9 present in these cells 
(Lande and Gilliet, 2010). The role of TLR10 in these cells has yet to be uncovered.  
The expression of TLR10 has so far only been assessed at the messenger RNA 
level, and my earlier attempts to detect the expression of the TLR10 receptor on the cell 
surface have been hampered by the lack of anti-TLR10 antibodies that recognize properly 
folded receptors. The commercially available anti-TLR10 antibodies were developed 
against a short synthetic TLR10 peptide and have a low affinity for the surface-expressed 
receptor. To evaluate the endogenous expression and facilitate functional studies of 
TLR10, here I report the generation and characterization of monoclonal antibodies (mAbs) 
against the extracellular domain of the receptor. I also measured TLR10 expression in 
various cell types isolated from human peripheral blood and found that granulocytes, 
natural killer (NK) cells, monocytes and T cells lacked detectable expression of TLR10, 
but human B cells expressed high cell surface levels of the receptor. The monoclonal 
antibodies generated in this study will serve as powerful experimental tools to further 
characterize TLR10 expression in various tissues and cell types, and ultimately define 
this orphan receptor’s biological functions. 
Materials and Methods 
Plasmid and protein purification- The TLR10 extracellular portion containing aa 
20-474 was cloned into a modified pDisplay vector for expression of the TLR10 
extracellular domain. Plasmid construction and protein purification were described in 
detail in the Chapter Three. (This work and protein purification was performed by 
another graduate student, Diana Rose Ranoa, in the Tapping laboratory.) 
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Generation of anti-TLR10 mAb through mice immunization and establishment of 
hybridoma clones- This work was performed in part by the Immunological Resource 
Center (University of Illinois at Urbana-Champaign). Five BALB/c mice were 
immunized by intraperitoneal (i.p.) injection of 50 µg TLR10 protein. Three weeks after 
initial priming, mice were boosted twice in 3-week intervals by i.p. injection of 25 µg of 
TLR10 protein. On week 8, small volumes of blood were collected from each immunized 
mouse to evaluate antibody responses through ELISA and flow cytometric staining of 
HEK 293T cells expressing TLR10 on their cell surface. The mouse with the highest 
antibody titer and receptor staining potential was selected by performing a final boost 
through i.p. injection of 25µg of TLR10 protein. On week 11, spleenic cells were 
collected and fused with myeloma cells.  
When viable hybridoma colonies were apparent (approximately 600 clones were 
isolated), culture supernatant from mature clones was screened for antibody production 
by ELISA. 100 µl of supernatant from hybridoma cells were added to microtiter plates 
that were coated overnight with 5 µg/ml of either TLR10 protein or TLR1 protein, and 
incubated for 1h at room temperature. After plate washing at the end of the incubation, 
detection of antibody-antigen binding was performed by the addition of horse radish 
peroxidase (HRP)-conjugated donkey anti-mouse (Jackson ImmunoResearch laboratories, 
West Grove, PA) at a concentration of 0.15 µg/ml for additional 30 min incubation. The 
colorimetric signal was measured after addition of o-phenylenediamine substrate and 
hydrogen peroxide at 490 nm.  
The hybridoma clones with positive ELISA results were further screened by flow 
cytometric analysis. HEK 293T cells were transfected with a vector carrying FLAG-
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tagged TLR10, FLAG-tagged TLR1 and empty vector respectively in a 10-cm tissue 
culture dish by using the calcium chloride transfection method. Two days post-
transfection, cells were removed from the plate and transferred to 96-well PCR plates at a 
density of approximately 2x105 cells per well. Cells were then incubated on ice with 50 
µl of each hybridoma supernatant for 30 min followed by incubation with FITC-
conjugated donkey anti mouse IgG (Jackson ImmunoResearch laboratories). Cells were 
then washed, fixed, and analyzed for surface TLR expression using a FACSCanto (BD 
Bioscience, San Jose, CA). 
Selected hybridoma clones were expanded and subclones were established by 
limiting dilution. The subclones were screened by using the same processes described 
above. The isotype of the mAbs was determined using the mouse ELISA rapid antibody 
isotyping kit (Thermo Scientific, Rockford, IL). 
Blocking antibody screening- The human colonic epithelial cell line SW620 was 
transiently co-transfected with the chimeric receptor TLR10-1, TLR2, an IL-8 promoter 
driven firefly luciferase reporter and a Renilla luciferase transfection control reporter in a 
10-cm tissue culture dish (see Chapter Three for details). One day post-transfection, cells 
were trypsinized and re-seeded into 96-well plates with a total volume of 100 µl. There 
are enough cells growing on a 10-cm tissue culture dish to approximately re-seed 1.5 96 
well plates. The following day, 50 µl of culture media were replaced with the same 
amount of the hybridoma supernatant and the anti-TLR10 antibodies in the supernatant 
were allowed to bind to TLR10-expressing cells for 30 minutes prior to stimulation with 
Pam3CSK4 at 20 ng/ml for 6 hours. At the end of stimulation, cells were washed with 
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PBS buffer and subsequently lysed in 25 µl of passive lysis buffer for 20 minutes. 15 µl 
of the cell lysate were analyzed for luciferase activity as described previously. 
Antibody purification- The selected hybridoma clones were cultured at 37°C, 7.5% 
CO2 in DMEM containing 10% FBS, 2mM L-glutamine and aminopterin (the medium 
was purchased from the IRC Facility, UIUC). For small-scale batch purification, 100 µl 
recombinant protein G Sepharose beads (GE healthcare, Piscataway, NJ) were added to 6 
ml of filtered culture supernatants, and incubated at 4oC overnight. Protein G beads were 
recovered by centrifugation at 3000 x g for 15 minutes at 4oC. The beads were washed 
with 3 ml binding buffer (20mM sodium phosphate buffer pH 7.0), and the antibody was 
eluted with 50 µl of 0.1M glycine-chloride (pH 2.5) in a 50µl volume followed by 
addition of 20 µl neutralizing buffer Tris-Cl (pH 9.0). The eluted antibody was dialyzed 
overnight against PBS (pH 7.4) at 4oC and the concentration was measured using 
bicinchoninic acid assay (BCA).  
When the growth of hybridoma clones reached high confluence, the media was 
switched to Hyclone SFM4MAb-Utility supplemented with L-Glutamine, a serum-free 
hybridoma growing medium. The culture supernatant was then collected and filtered to 
remove the cell debris. A volume of 200 ml of the supernatant was loaded on a pre-
packed1 ml protein G column using the AKTA Prime purification system (GE Healthcare) 
at a flow rate of 1.0 ml/min. The column was then washed with 15 ml binding buffer and 
the antibody was eluted with 0.1M glycine-chloride (pH 2.5) in 3.0-ml fractions into 
tubes containing 100ul of neutralizing buffer 1M Tris-Cl (pH 9.0). Antibodies were 
concentrated using an Amicon ultra centrifugal filter device with 10,000 nominal 
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molecular weight limit (Millipore, Bedford, MA) followed by dialysis and concentration 
measurement. 
Detection of endogenous TLR10 from blood leukocytes by flow cytometric 
analysis- Blood samples were obtained from normal healthy volunteers under a protocol 
approved by the University of Illinois IRB. Peripheral blood leukocytes were prepared by 
applying erythrocyte lysing buffer (BD Bioscience) to whole blood followed by cell wash 
using PBS buffer. The sample size was maintained at 2-3 x 105 cells per treatment. 
A FACSCanto (BD Bioscience) was used for one- or two-color flow cytometry 
and data were analyzed using FCS Express software. Cell surface expression of 
endogenous TLR10 was measured using mAb clone 3C10C5. Isotype control antibody 
mouse IgG1 and FITC-conjugated anti-human CD3, CD14, CD16 and CD19 were 
purchased from eBioscience (San Diego, CA). To minimize FcR-mediated mAb binding, 
2% rabbit serum was included in the flow cytometric staining buffer. A three-step 
staining protocol was performed to detect surface TLR10 on primary cells, which 
involves incubation of cells with an anti-TLR10 antibody at a concentration of 20 µg/ml 
followed by biotinylated donkey anti-mouse IgG, and finally with allophycocyanin-
conjugated streptavidin (Jackson ImmunoResearch laboratories). For co-staining of 
surface TLR10 and cell surface markers, cells were further incubated with FITC-
conjugated antibodies following surface TLR10 staining. 
Results 
Production of antibodies against human TLR10 in mice- Like other TLRs, TLR10 
is characterized by an extracellular domain (ECD), containing 19 leucine-rich repeat 
motifs responsible for ligand recognition, followed by a transmembrane domain and an 
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intracellular TIR signaling domain. To investigate the biological function of TLR10, I 
developed monoclonal anti-TLR10 antibodies using purified and properly folded human 
TLR10 ECD protein as the immunizing antigen. This purified TLR10 ECD, expressed in 
HEK 293F cells as a soluble protein, comprised aa 20-474 (LRR 1-18) which includes 
the essential region required for ligand recognition and protein-protein interaction. To 
generate antibodies against TLR10, five BALB/c mice were immunized three times 
within 8 weeks by i.p. injection of TLR10 protein. Blood samples were taken from these 
mice to assess anti-TLR10 antibody titer in the serum. The reactivity between TLR10 and 
its antiserum was measured by adding serially-diluted mouse antiserum or a control 
serum from a non-immunized mouse to microtiter plates coated with purified TLR10 
protein. Using ELISA, the binding of the antibody in the serum to the TLR10 antigen was 
detected by the addition of HRP-conjugated anti-mouse polyclonal antibody. As shown in 
Fig. 4.1A, the antisera from mice 0, LL and RR exhibited high reactivity to the antigen 
even when diluted 6400 fold. Slightly lower antibody titers were observed in mice L and 
R. As expected, the control serum did not show specificity toward TLR10 protein.  
The anti-TLR10 sera were further examined for their ability to detect the full-
length receptor expressed on cell surface. Using each antiserum as a primary antibody, 
flow cytometric staining of 293T cells was performed following transfection of Flag-
tagged TLR10. As a positive control, cells were stained by anti-FLAG antibody.  Flow 
cytometry analysis revealed that the antisera from the five immunized mice showed 
variable binding to surface TLR10 (Fig. 4.1B). The data are shown as a quantification of 
fold increase in mean fluorescence intensity values between TLR10-expressing cells and 
those transfected with an empty vector. The anti-TLR10 antiserum from mouse LL 
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exhibited the highest cell surface staining of TLR10 among all the antisera. The serum 
from mouse RR showed a similar antibody titer as that for mouse LL for the ELISA assay, 
but limited cell surface staining ability when compared with the serum from mouse LL. It 
is worth noting that the fluorescence signal obtained with mouse LL serum as the primary 
antibody is 2.5 fold higher than surface staining using the anti-FLAG antibody. Fig. 4.1C 
shows a typical histogram profile of surface TLR10 staining by the antiserum from 
mouse LL which created a larger fluorescence shift than that of anti-FLAG antibody, 
indicating the anti-TLR10 antibodies in the serum strongly bind to full-length TLR10. 
In addition, I wished to screen for an inhibitory antibody to TLR10; one that is 
capable of abrogating TLR10ECD binding to ligand and/or the TLR2 coreceptor. To this 
end, the chimeric TLR10 receptor TLR10-1, together with TLR2, were expressed in 
SW620 cells to provide a functional readout. Cells were incubated with varying amounts 
of each anti-TLR10 antiserum for 30 minutes prior to stimulation with lipopeptides. A 
partial inhibitory effect of the antiserum from mouse LL on TLR10-mediated cell 
activation was observed (data not shown). Finally, mouse LL was chosen for a final 
booster shot before sacrifice and fusion of spleen cells to generate hybridoma clones. 
Establishment of hybridoma subclones expressing anti-TLR10 mAb- Splenocytes 
from the mouse LL were fused with myeloma cells, and the resulting hybridomas were 
screened for the secretion of anti-TLR10 antibodies by ELISA. To exclude antibodies 
that cross-react with TLR1, which shares the highest sequence homology and ligand 
specificity with TLR10, two sets of ELISAs were performed using plates coated with 
TLR1 protein or TLR10 protein, respectively. Hybridoma supernatants from 52 out of 
600 wells were found to contain antibodies that were specific to TLR10 but not to TLR1. 
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These 52 hybridoma clones were further screened for binding to surface-expressed 
TLR10 using flow cytometric analysis. This screening identified a total of 17 hybridoma 
clones that exhibited specific reactivity to TLR10. However, the supernatants of these 
clones failed to effectively inhibit TLR10-dependent cell activation in the bioassay 
described above. Five out of the 17 clones (P2G3, P3C10, P5C2, P3G10, P5H9), whose 
supernatants showed strong immunostaining ability, were subcloned by limiting dilution. 
The subclones generated were again tested for TLR10 specificity by ELISA and flow 
cytometric analysis. A total of 15 subclones (3 per clone), which met the criteria in the 
two aforementioned assays and exhibited no cross-reactivity to TLR1, were propagated 
and established as anti-TLR10 hybridoma cell lines. Fig. 4.2 shows a summary of the 
detection of surface-expressed TLR10 using the supernatant of established hybridoma 
subclones. All 15 subclones efficiently recognize TLR10 but not TLR1. In comparison, 
the cell surface expression of TLR1 was readily measurable using the control antibody 
anti-FLAG. 
Characterization of anti-TLR10 mAb purified from hybridoma subclones- With 
established hybridoma lines, I next characterized the mAbs purified from the supernatant 
of the 15 subclones. Using an immunoglobulin (Ig) isotyping kit, the mAb expressed by 
all 15 subclones were identified as mIgG1 subclass with kappa light chain. To detect the 
titer of the mAbs in ELISA, various concentrations of individual mAbs were added to 
TLR10 protein immobilized on microtiter plates. As shown in Fig. 4.3A, the mAbs 
derived from the same cellular origin exhibited uniform reactivity to the antigen. All 
mAbs recognize the TLR10 protein at a concentration as low as 0.1 µg/ml and robust 
ELISA signals are achieved when a 1 µg/ml concentration is used. Clones P2G3, P3C10 
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and P5C2 appear to be more suitable for detecting the immobilized TLR10 protein than 
clones P5G10 and P5H9 since the colorimetric signals generated from the former group 
were stronger than those of the latter group.  
The amount of each mAb required for detection of surface-expressed TLR10 was 
also examined. Various concentrations of individual mAbs were used as primary 
antibodies to bind to TLR10 expressed on the surface of transiently-transfected HEK 
293T cells. Flow cytometry analysis revealed that the anti-TLR10 mAbs are capable of 
detecting surface TLR10 at a concentration of 10µg/ml (Fig. 4.3B). The antibodies 
derived from subclones P3C10, P5C2, P5G10, and P5H9 generated a stronger staining 
signal compared to anti-FLAG antibody binding, which was added at a higher 
concentration (20 µg/ml). The antibodies from subclones of P2G3 produced a similar 
fluorescence signal as the anti-FLAG antibody. To further confirm the specificity of these 
mAbs, TLR1- or TLR6-transfected 293T cells were assessed for staining with these anti-
TLR10 antibodies. As expected, no cross-reactivity was observed indicating that these 
mAbs are highly specific for TLR10 (data not shown). Altogether, the data demonstrated 
that the 15 batch-purified mAbs are suitable for both ELISA and flow cytometry analysis. 
Detection of endogenous TLR10 on human peripheral blood cells- To characterize 
the expression profile of endogenous TLR10 protein, I investigated the receptor 
expression profile in human peripheral blood cells by flow cytometry. After removal of 
red blood cells, white blood cells were incubated with either anti-TLR10 mAb (purified 
from clone P3C10C5) or a mouse IgG1 isotype control antibody, followed by biotin-
streptavidin staining steps. A dot plot of white blood cells forward and side scatter signals 
shows three distinctive cell populations representing granulocytes, monocytes and 
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lymphocytes (Fig. 4.4A). The expression of TLR10 was analyzed by gating on each cell 
population. Fig. 4.4B reveals that TLR10 is not present on the surface of monocytes and 
granulocytes. The gate was verified by staining cells with antibodies against cell surface 
markers CD14 and CD16, which are known to be expressed on monocytes and 
granulocytes/natural killer (NK) cells, respectively (data not shown). In contrast, the anti-
TLR10 mAb stained a small portion of the lymphocyte population. To further identify the 
subpopulation of lymphocytes that express TLR10, I performed dual color flow 
cytometry staining (Fig. 4.4C). Co-staining of blood cells with an anti-TLR10 mAb and 
an antibody against a known lineage marker for either B cells (CD19) or T cells (CD3) 
revealed that the anti-TLR10 mAb clearly stained all CD19+ cells, but not CD3+ cells. 
Taken together, the result suggests that TLR10 receptor expression is highly restricted to 
B cells, while granulocytes, NK cells, monocytes and T cells lacked detectable amounts 
of endogenous TLR10 on their surface. 
Discussion 
Since the discovery of mammalian TLRs, a wide variety of antibodies against 
TLRs 1-9 have been generated and applied to numerous studies aimed at assessing 
expression levels in different cell types, regulation of expression and functional analyses. 
Human TLR10 was first cloned in 2001; however, it has remained as an orphan member 
of the human TLRs due to lack of understanding of its natural ligands and signaling 
pathways. The commercially-available anti-TLR10 antibodies poorly detect the receptor 
expressed on cell surface and are more suitable for use in immunoblot assays. The goal of 
this study was thus to generate an effective anti-TLR10 monoclonal antibody to allow 
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better understanding of expression of TLR10 and to facilitate more directed functional 
studies of the receptor.  
Genetic studies reveal that the mouse TLR10 is a pseudogene due to the presence 
of gaps and retroviral gene insertions (Hasan et al., 2005). This allowed me to develop 
anti-human TLR10 antibodies in mice. Purified TLR10ECD was used as the antigen to 
immunize mice and the resulting hybridoma clones, as well as subclones, were screened 
for production of antibodies that were specific for human TLR10 by performing both 
ELISA and flow cytometric staining of TLR10-transfected 293T cells. To exclude clones 
with cross-reactivity to TLR1, purified TLR1 ECD and HEK 293T cells expressing 
surface TLR1 were included in ELISA and cell staining assays, respectively. An initial 
ELISA screen of 600 hybridoma clones provided 52 positives and surface protein 
staining revealed that 17 out of 52 clones were capable of detecting TLR10 expressed on 
the cell surface. All 17 clones secrete mAbs that can specifically react with TLR10 
protein, but not with TLR1 or TLR6. The affinity measurements performed by another 
graduate student, Diana Rose Ranoa, in the Tapping laboratory revealed that the affinity 
of the anti-TLR10 mAb P3C10C5 for purified TLR10 ECD has a dissociation constant 
(KD) of 5.09e-10, which indicates strong binding between the antibody and antigen. It 
should be noted that two commercially available antibodies (2A11 from GeneTex, and 
386A from Imgenex) were approximately 5 fold less sensitive than the mAb developed in 
this study in detecting TLR10 ECD immobilized on microtiter plates and clone 2A11 
failed to detect TLR10 expressed on the cell surface (data not shown).  
Additional screening for blocking antibodies was performed using a bioassay in 
which individual hybridoma supernatant or purified antibody was incubated with SW620 
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cells transfected with TLR2 and TLR10-1 prior to stimulation with lipopeptide agonists. 
Unfortunately, the screening failed to yield an antibody that effectively inhibits 
lipopeptide-mediated TLR2/10 heterodimerization. The results suggest that the epitope of 
the established anti-TLR10 antibodies is located outside of the region for ligand binding 
and receptor dimerization in TLR10.  
Using the purified antibody, I then examined TLR10 expression in human 
peripheral blood cells and detected a robust and exclusive expression of TLR10 in B cells. 
Previous studies have investigated the mRNA of TLR10 in various cell types, showing 
that the level of TLR10 message is high in B cells (Bourke et al., 2003; Hornung et al., 
2002). Using the anti-TLR10 mAb I have developed, the present study has shown that 
human B cells express high endogenous levels of cell surface TLR10. The B cell pool in 
the peripheral blood of healthy adults consists of approximately 60% naïve B cells and 40% 
memory B cells (Klein et al., 1998). Data shown in Fig. 4.4C indicate that the anti-
TLR10 mAb stained the entire B cell population in the peripheral blood of this donor, 
suggesting that TLR10 is present in both naïve and memory B cells. In support of this 
finding, TLR10 mRNA has been found in all stages during B cell differentiation with the 
exception of pre-B cells (Bourke et al., 2003; Hasan et al., 2005).  In addition, another 
study of B cells derived from human peripheral blood has shown that the TLR10 mRNA 
is detected at relatively low levels in naïve B cells with higher levels in memory B cells 
(Bernasconi et al., 2003). I have observed that a small subpopulation of the B cells 
appears to possess extremely high levels of surface TLR10 expression represented by the 
intensive fluorescence signal after TLR10 staining which may correspond to the memory 
B cells. Additional flow cytometric costaining of blood cells with anti-TLR10 mAb and 
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lineage markers CD19 as well as CD27, a marker for somatically mutated B cells, are 
required to verify the expression of TLR10 protein in blood B cell subpopulations 
(Bohnhorst et al., 2001).  
In the analysis of TLR10 expression in human peripheral blood cells, I observed 
variation in the percentage of TLR10 positive cells detected in peripheral blood from 
donor to donor, ranging from 2.9% to 9.8% of the lymphocytes. Some blood donors 
possess limited surface TLR10-expressing cells even after the amplification of flow 
cytometric signal by a biotinylated secondary antibody and a fluorophore-conjugated 
streptavidin. Co-staining for known cell markers in these low TLR10-expressing cells 
revealed that TLR10 was expressed only on a small fraction of the B cell population, and 
was undetectable on the rest of the B cells as well as other cell types. This observation 
suggests that certain genetic or environmental factors influence the levels of surface 
expressed TLR10. The anti-TLR10 mAbs established in this study are very useful tools to 
further define both surface and intracellular TLR10 expression, which will help uncover 
the mechanisms behind the difference in TLR10 expression among donors.  
In addition to the readily detectable TLR10 transcripts in B cells, previous studies 
on the expression pattern of TLRs have shown that the TLR10 mRNA level in resting B 
cells was quickly induced after BCR engagement or treatment with B cell mitogens 
(Bernasconi et al., 2003; Bourke et al., 2003). An increase in TLR10 expression has also 
been observed in naïve B cells derived from infected tonsils (Mansson et al., 2006). The 
mAbs generated in this study will enable us to evaluate the regulation of TLR10 
expression at the protein level. Together, the expression of TLR10 on B cells and its up-
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regulation upon cell activation suggest that this receptor likely plays an important role in 
B cell function. 
Low levels of TLR10 mRNA on pDCs have been reported in a few studies. pDCs 
are located between the small lymphocytes and monocytes in a dot plot with scatter 
signals of human blood cells, and accounts for 0.2%-0.6% of all white blood cells 
(Dzionek et al., 2000). While a slight fluorescence increase in TLR10 staining compared 
to the isotype control was observed in such a cell population, the present study was 
unable to clearly reveal TLR10 expression in pDCs possibly due to the low expression 
level of the receptor and/or scarcity of pDCs in blood cells. Additional flow cytometric 
staining using purified pDCs and/or pDC-specific cell surface marker BDCA-2 will be 
helpful for identifying TLR10 protein expression in this cell type. 
In conclusion, high affinity mAbs against the extracellular domain of TLR10 were 
generated in this study and used to detect physiological receptor expression. The 
antibodies provide powerful experimental tools to further characterize TLR10 expression 
and explore molecular interactions and pathways in which TLR10 functions. All these 
should contribute to a better understanding of the immune function of human TLR10.  
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Figures 
 
 
 
Figure 4.1. Screening for the presence of anti-TLR10 antibody in serum isolated from 
mice immunized with TLR10 protein. (A) Screening by ELISA. Serially-diluted sera from 
five immunized mice were added to microtiter plates coated with purified TLR10 and 
incubated for 1 hour. Antibody binding was detected by the addition of HRP-conjugated 
anti-mouse and OPD substrate, and the colorimetric reaction was measured at 490nm. (B) 
Screening by flow cytometry. HEK 293T cells transfected with either Flag-TLR10 vector 
or an empty vector were incubated with anti-flag (M2) or serum diluents from immunized 
mice, followed by incubation with biotin-conjugated anti mouse antibody and finally with 
PE-conjugated streptavidin. After labeling, cells were analyzed by flow cytometry to 
screen for mouse sera that contain anti-TLR10 antibodies. Data are presented as the fold 
increase in fluorescent signal from TLR10-expressing cells relative to empty vector 
expressing cells. The values represented the average of two independent staining. (C) 
Flow cytometry histogram profile of HEK 293 cells transfected with either Flag-TLR10 
(solid line) or empty vector (dashed line) and stained with anti-Flag or serum from mouse 
LL as indicated. 
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Figure 4.2. Summary of flow cytometry staining of cell surface TLR10 (black bars) or 
TLR1 (white bars) using the supernatant from the 15 selected hybridoma subclones. HEK 
293T cells were transfected with empty vector FLAG-CMV, FLAG-TLR10 or FLAG-
TLR1 respectively. After 48 hours, cells were incubated with anti-FLAG (M2) or the 
supernatant of the indicated hybridoma subclones followed by staining with biotin-
conjugated anti-mouse Ig antibody and PE-conjugated streptavidin. After labeling, cells 
were analyzed by flow cytometry for surface expression. Data are presented as the fold 
increase in fluorescent signal from TLR10- or TLR-1 expressing cells relative to non-
TLR (CMV) expressing cells. All 15 subclones efficiently bound TLR10, and showed no 
cross reactivity toward TLR1. 
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Figure 4.3. The detection limit of purified anti-TLR10 antibodies to TLR10 protein in 
ELISA (A) and flow cytometry (B) assays. (A) TLR10 protein-coated wells were 
incubated with indicated antibodies at different concentrations. The amount of antibody 
binding was detected through an HRP-conjugated anti-mouse Ab. (B) HEK 293T cells 
were transfected with either empty vector FLAG-CMV or FLAG-TLR10. After 48 hours, 
cells were incubated with anti-FLAG (20 µg/ml) or batch-purified mAbs from 15 
subcolones at 10 µg/ml, 1 µg/ml and 0.1 µg/ml. Subsequently, cells were incubated with 
FITC-conjugated anti mouse antibody. After labeling, cells were analyzed by flow 
cytometry for surface expression TLR10. Data are presented as the fold increase in 
fluorescent signal from TLR10-expressing cells relative to non-TLR10 (CMV) 
expressing cells. A concentration of 10 µg/ml was the minimum amount needed for 
detection of TLR10 expression on the cell surface. 
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Figure 4.4. Detection of endogenous TLR10 in human peripheral blood cells. (A) Scatter 
profile of various white blood cell populations isolated from peripheral blood of a healthy 
donor. (B) Blood cells were stained with anti-TLR10 mAb (20 µg/ml) (red) or isotype 
control (black), and subsequently incubated with biotin-conjugated anti-mouse Ig 
antibody and APC-conjugated streptavidin. In each histogram, cells were gated at the 
indicated population. (C) Dual color staining for TLR10-expressing cells in the 
lymphocyte population.  The blood cells were stained with anti-TLR10 mAbs in a three-
step staining protocol described above followed by staining with FITC-conjugated CD19 
or CD3. Dot plots were gated in the lymphocyte population. Numerical values indicate 
the percentage of cells in the respective quadrant.  
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CHAPTER FIVE 
CONCLUSION 
Summary 
This dissertation research explores the innate immune sensing function of TLR10 
and uncovers novel synthetic agonists for TLR2. I have defined agonists for TLR10, the 
only remaining orphan human TLR, uncovered alternative mechanisms of activating 
TLR2 subfamily members, and provided insights for designing TLR-targeted 
immunotherapies and vaccine adjuvants. This chapter will summarize the major findings 
of the dissertation, assess their contribution, and explore future research directions. 
Chapter Two of this thesis presents the identification of novel synthetic TLR2 
agonists by screening a chemical library. The initial objective of the screening included a 
search for TLR10 ligands as well as novel TLR2 agonists. The high throughput screen of 
24,000 synthetic compounds identified 16 novel TLR2 agonists that utilize TLR1, TLR6 
or both as coreceptors. These compounds represent the smallest agonists for TLR2 to date 
and their aromatic structural features are unrelated to any known TLR2 agonists. The 
observations led me to carefully characterize the three most potent compounds from 
different perspectives. I first established that these compounds activate cells in the 
nanomolar range and are highly specific for TLR1 and TLR2. Although the compounds 
possess distinct structural features from known lipopeptide agonists, they do not exhibit 
synergistic activity, nor do they act as antagonists toward natural TLR2 activators, which 
suggests that the compounds occupy binding sites different from those of lipopeptides on 
the receptors. Motivated by this finding, I further studied the mechanisms by which 
TLR1 recognizes the compounds. Domain-swapping experiments in which LRRs were 
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exchanged between TLR1 and TLR6 showed that, similar to lipopeptides, the central 
region comprised of LRRs9-12 of the extracellular domain of TLR1 is essential for 
recognizing the chemical compounds (Omueti et al., 2005). Detailed analysis was carried 
out using TLR1 variants which have been shown to affect responses to lipopeptides. The 
data revealed that while unimpaired TLR2/1 dimer interaction is required to mediate 
efficient responses to both chemical compounds and lipopeptides, different residues 
contribute to lipopeptide-mediated and compound-mediated cell activation. Given the 
structural traits of the compounds and the differences observed in TLR1 variants, it is 
proposed that the compounds bind directly within the interface of the TLR2/1 
heterodimer. Finally, the compounds were shown to activate human peripheral blood 
monocytes to produce cytokines, which suggests that they may have therapeutic 
applications as vaccine adjuvants. It also should be noted that compounds with similar 
structures have been independently identified in the chemical library. This finding 
validates the screening assay in this study as a powerful approach for identifying novel 
TLR2 agonists.  
It remains unclear why the search failed to yield a compound that activates 
TLR10. This question was answered in Chapter Three in which I found that TLR10 fails 
to activate typical TLR-induced signaling outputs, including NF-B-, IL8- and IFN-β-
driven reporters. Thus, the high-throughput chemical library screening which used an IL-
8-driven reporter could not have been activated by TLR10 alone or in combination with 
TLR2. In Chapter Three, I continued to define a ligand for TLR10 through creation of a 
chimeric receptor TLR10-1 which contains the ECD of TLR10 and the intracellular 
signaling domain of TLR1. The key assumption is that lipopeptides could also be 
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agonists for TLR10 based upon the phylogenetic evidence that TLR10 is most related to 
TLR1 and TLR6.  Using the chimeric receptor, I demonstrated that TLR10 cooperates 
with TLR2 in the sensing of lipopeptides as well as a variety of microbial-derived 
agonists shared by TLR1, but not TLR6. This finding was confirmed by showing that the 
chimeric receptor TLR10-1 fully restored the response of TLR1-deficient macrophages to 
triacylated lipopeptides. Furthermore, the requirement of TLR2 in TLR10-mediated 
ligand recognition was verified by the following evidence: 
1) TLR10 and TLR2 colocalize in early phagosomes in response to stimulation with 
zymosan particles. 
2) TLR10 coimmuneprecipitates with TLR2, and the association between the 
receptors increases with the addition of tri-acylated lipopeptides. 
3) Purified ECDs of TLR2 and TLR10 physically interact with each other in a 
ligand-dependent manner. 
I then characterized and compared the mechanisms responsible for ligand recognition by 
TLR10 and TLR1. A computational model of TLR2/10/lipopeptide was built based on 
the solved crystal structure of TLR2/1/lipopeptide (Jin et al., 2007). The model shows 
that TLR10 preserves the TLR2 dimer interface and the lipopeptide binding channel 
found in TLR1. The relevance of the model is supported by a domain-swapping 
experiment which demonstrated that the LRRs 6-17 of TLR10 ECD are responsible for 
lipopeptide specificity. Additionally, site-directed mutagenesis of key amino acid 
residues, predicted by the model to be functionally important, led to an attenuated 
response to lipopeptides. When compared to the corresponding residues in TLR1, I found 
that the interactions of the two receptors with lipopeptides are similar, but they appear to 
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possess subtle differences at the TLR2 dimer interface. Interestingly, the novel chemical 
compounds which likely fit in the interface of the TLR2/1 heterodimer showed limited or 
no activity towards the TLR2/10 heterodimer. Finally, a proximal signaling adapter 
MyD88 was shown to be recruited to the TLR2/10 complex, and this association was 
enhanced by the addition of lipopeptides. The result suggests that the interaction of 
MyD88 with the TLR2/10 heterodimer is distinct from that of other TLR2 family 
members which may account for the failure of this complex to induce signals typically 
associated with MyD88 activity.  
Chapter Four describes the generation and characterization of anti-TLR10 
monoclonal antibodies that will facilitate functional studies of TLR10. A purified and 
properly folded human TLR10 ECD protein was used as the antigen to immunize five 
mice for production of antibodies against TLR10. The resulting hybridoma clones were 
screened for specific binding using both ELISA with purified TLR10 protein as antigen 
and flow cytometric staining of 293T cells transfected with Flag-tagged TLR10. A total 
of 17 hybridoma lines were isolated that secrete monoclonal antibodies that bind strongly 
to TLR10, but to neither TLR1 nor TLR6. Five out of the 17 clones were subcloned by 
limiting dilution and screened in the two aforementioned assays. Finally, a total of 15 
subclones were established as anti-TLR10 hybridoma cell lines. All mAbs recognize the 
purified TLR10 ECD at a concentration as low as 0.1 µg/ml and detecte surface 
expressed TLR10 at a concentration of 10 µg/ml. The antibodies derived from most of 
these subclones generated a stronger TLR10 staining signal against Flag-tagged TLR10 
than that of the anti-Flag antibody. The purified mAbs were used to examine endogenous 
TLR10 expression in human peripheral blood. Granulocytes, NK cells, monocytes and T 
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cells lack detectable expression of TLR10, but human B cells express high cell-surface 
levels of the receptor, which represents a unique expression profile among mammalian 
TLRs.  
Significance and Future Work 
TLRs are evolutionarily conserved receptors serving as sensors for a wide variety 
of pathogen-associated patterns (PAMPs) from viruses, bacteria, fungi and protozoa. 
Upon recognition of their agonists, TLRs mediate immediate protection for the host and 
modulate the action of the adaptive immune system (Medzhitov and Janeway, 1997a; 
Takeda et al., 2003). Unlike most TLRs which signal as homodimers, TLR2 requires 
either TLR1 or TLR6 for activity and the cooperative complexes enable TLR2 to 
recognize various bacterial and fungal cell wall components. TLR1 and TLR6 share 
highly homologous intracellular domains and TLR2/1 and TLR2/6 complexes mediate 
identical signaling pathways (Farhat et al., 2008). TLR2 is expressed on various cells of 
both the innate and adaptive immune system. The engagement of TLR2 complexes with 
their ligands leads to the activation of NF-B, AP-1 and other transcription factors which 
induce pro-inflammatory responses. Stimulation with TLR2 agonists also provides 
specific signals to modulate B cell responses to antigens (Brikos and O'Neill, 2008; 
Chiron et al., 2008). 
Studies using TLR2 knockout mice have indicated a role of TLR2 in protecting 
the host from infectious diseases (Echchannaoui et al., 2002; Takeuchi et al., 2000). 
Receptor polymorphisms within the TLR2 subfamily have also been associated with 
various microbial infections (Misch and Hawn, 2008; Ogus et al., 2004). In addition, 
inappropriate or prolonged inflammation triggered through TLR2 has been implicated in 
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the development of chronic inflammatory disorders including arthritis, atherosclerosis 
and asthma (Kormann et al., 2008; Palsson-McDermott and O'Neill, 2007). Indeed, TLR2 
antagonists hold great promise in the treatment of chronic inflammatory diseases. On the 
other hand, TLR2 agonists are under investigation as vaccine adjuvants to modulate 
immune responses (O'Neill et al., 2009).  
The novel synthetic TLR2 activators described in Chapter Two represent the 
smallest molecules known to activate the TLR2/1 heterodimer. The characterization of 
these compounds identified an alternative mechanism of activation of the TLR2/1 
complex which may provide novel approaches for the TLR2-based design of vaccine 
adjuvants. Future work concerning the novel TLR2 activators could be directed at the 
generation of a secondary chemical library composed of analogues of the most potent 
compounds. The screening of the secondary library may yield compounds with stronger 
activity and pharmacologically favorable features.  
The TLR2 subfamily comprises TLRs 1, 2, 6 and 10. The genes encoding TLRs 1, 
6 and 10 share the same locus on the chromosome and are likely to have risen from gene 
duplication events. Based on phylogeny, TLR10 predates the generation of TLRs 1 and 6. 
As evolutionarily conserved receptors, TLRs evolved under strong purifying selection 
(Beutler and Rehli, 2002; Kimbrell and Beutler, 2001). The independent maintenance of 
TLR10 suggests a distinct biological role for this receptor. Defining the innate sensing 
and the immune function of TLR10 will contribute to a full understanding of the TLR2 
subfamily function.  
The finding that TLR10 senses triacylated lipopeptides and other microbial-
derived agonists shared by TLR1, but not TLR6, reveals for the first time the innate 
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sensing function of TLR10. The results described in Chapter Three firmly demonstrate 
that TLR10 requires TLR2 for innate immune recognition. Biological, biophysical and 
structural evidence was provided to support the long-standing prediction that TLR10 is a 
heterodimeric partner of TLR2. The fact that TLR10 cooperates with TLR2 in ligand 
sensing, but fails to induce typical TLR associated signaling events, suggests that TLR10, 
rather than further expanding the already wide ligand spectrum of TLR2, contributes to a 
signaling function distinct from that of other TLR2 subfamily members. In addition, 
protein expression studies using anti-TLR10 mAbs described in Chapter Four confirm 
that the high level of TLR10 protein is restricted to B cells, an expression pattern 
different from that of TLR1 and TLR6, which further suggests a functional divergence 
from the latter two receptors. 
The discovery that TLR10 shares ligand specificity with TLR1 calls for the re-
evaluation of previous studies using lipoproteins or other TLR2/1 agonists for the 
stimulation of human B cells. The treatment of purified B cells with the triacylated 
lipopeptide Pam3CSK4 induced IL-6 secretion and IgM secretion as well as the initiation 
of germinal center formation (Ganley-Leal et al., 2006; Mansson et al., 2006). Human 
multiple myeloma cell lines and chronic lymphocytic leukaemia cells respond to 
Pam3CSK4 with an enhanced survival rate (Bohnhorst et al., 2006; Muzio et al., 2009). It 
is very likely that TLR10 plays a role in these lipopeptide-mediated reactions given its 
high and regulatable expression in B cell lineages. It is also worth noting that the novel 
chemical compounds identified in Chapter Two are highly specific to TLR2/1, and do not 
activate TLR2/10. Therefore, these compounds may be used to distinguish between 
TLR1- and TLR10-mediated effects. 
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Although the expression of TLR10 in cell types other than B cells was not 
detected in this study, TLR10 transcripts have been found in pDCs and regulatory T cells 
(Bell et al., 2007; Hornung et al., 2002). In addition, the Tapping laboratory and other 
researchers have shown that TLR10 mRNA is inducible in macrophages upon 
differentiation or exposure to certain nanoparticles (Lucarelli et al., 2004). These cell 
types also express other TLR2 subfamily members to varying degrees. As pointed out in 
Chapter Three, the competition of TLR1 and TLR10 for ligand and coreceptors is likely 
to have significant functional consequences for host immune defense and inflammation, 
given the different signaling outputs of these two receptor complexes. The preliminary 
studies in the Tapping laboratory indicate that TLR10 acts as a decoy receptor to dampen 
cell responses to lipopeptides in myeloid cells.  
Moreover, TLR10 is a nonfunctional pseudogene in mice, but intact TLR10 
sequence has been identified in rat, bovine and porcine chromosomes (Opsal et al., 2006; 
Shinkai et al., 2006). The future design of vaccine adjuvants or TLR2 antagonists should 
be tested in an animal model with a functional TLR10 gene, so as to have more relevance 
to human responses. 
Finally, the structural model of TLR2/10/lipopeptide complex and functional 
studies of TLR10 have provided a molecular basis for the rational design of TLR10-
specific agonists. The unique expression pattern of TLR10 in B cells suggests a potential 
use of TLR10 in selective targeting of B cells during immunotherapy.  
A logical extension of this study is to explore the role of TLR10 in human 
immune defense. The directions currently being pursued in the Tapping laboratory 
include: assessing the ability of TLRs 1, 6 and 10 to compete for the coreceptor TLR2 
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and their agonists using soluble forms of the receptors in biophysical assays, determining 
the signaling function of TLR10 through transient transfection studies as well as the 
generation of myeloid cells lines that stably express TLR10, and exploring the in vivo 
function of TLR10 in whole animal models by generating TLR10 transgenic mice. Based 
on the preliminary studies, we propose that TLR10 dampens classical TLR2-mediated 
activation in myeloid cells presumably through recruitment of the proximal signaling 
adapter MyD88 in a manner distinct from that for TLR2/1 and TLR2/6 complexes. 
Similarly, TLR10 may also play an inhibitory role in B cell proliferation and 
differentiation. Further work on the identification of a TLR10 specific ligand and the 
generation of an inhibitory anti-TLR10 antibody should help verify the model we have 
proposed. 
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APPENDIX A 
SUPPLEMENTARY MATERIALS 
Figures 
 
Figure A.1. Surface expression of CD4-TLRs constructs. 293T cells were transfected with 
indicated CD4-TLR constructs (solid line) or an empty vector (dotted line) at the 
concentration of 1 µg/ml.  Cells were stained sequentially with a monoclonal antibody for 
mouse CD4, a biotin-conjugated donkey anti-mouse secondary antibody and a 
streptavidin-PE-conjugated tertiary antibody. Surface expression was analyzed by flow 
cytometry. 
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Figure A.2. Surface expression of TLR10 chimeric constructs. (A) 293T cells were 
transfected with a FLAG-tagged wild-type TLR10, a FLAG-tagged TLR10-1 or an empty 
vector at the concentration of 2.5 µg/ml.  Cells were stained sequentially with the anti-
FLAG mAB (M2), a biotin-conjugated donkey anti-mouse secondary antibody and a 
streptavidin-PE-conjugated tertiary antibody. (B) 293T cells were transfected with a 
FLAG-tagged wild-type TLR1 and a FLAG-tagged TLR1-10 and an empty vector at the 
concentration of 2 µg/ml.  Cells were stained sequentially with the anti-FLAG mAb (M2) 
and FITC-conjugated donkey anti-mouse secondary antibody. Surface expression was 
analyzed by flow cytometry. 
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Figure A.3. Surface expression of TLR10 mutants. 293T cells were transfected with 
indicated FLAG-tagged TLR10-1 (solid line), FLAG-tagged TLR10 mutants (solid line) 
or an empty vector (dotted line) at the concentration of 2.5 µg/ml.  Cells were stained 
sequentially with the anti-FLAG mAb (M2), a biotin-conjugated donkey anti-mouse 
secondary antibody and a streptavidin-PE-conjugated tertiary antibody. Surface 
expression was analyzed by flow cytometry. 
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Figure A.4.  TLR10 fails to sense chemical compound-agonists. SW620 cells were 
cotransfected with vectors encoding the indicated TLRs, an IL-8 driven firefly luciferase 
gene and a Renilla luciferase control. Two days after transfection, cells were stimulated 
with different concentrations of compound A, B or C for 6 hours and cell lysates were 
analysed for dual luciferase activity. After correcting for transfection efficiency using 
Renilla luciferase, all values were normalized to those of unstimulated cells transfected 
with empty FLAG-CMV vector. Error bars represent the standard deviation of three 
independent wells stimulated with the indicated concentration of agonist. 
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Tables 
  
Table A.1 Cloning Primers. 
Primer Name Sequence (5’--3’) 
CD4-TLRs constructs 
CD4 Forw* GGA AGC TTA CCA CCA TGT GCC GAG CCA TC  
CD4 Rev* AAC TCG AGC ACT GTC TGG TTC ACC CCT CTG GAT AAA ACC TGG 
TLR1 Forw* ATT CTC GAG ATA ACT CTG CTG ATC GTC ACC ATC 
TLR1 Rev* GCG TCT AGA CTA TTT CTT TGC TTG CTC TGT CAG C 
TLR2 Forw* ATT CTC GAG ACA GCA CTG GTG TCT GGC ATG 
TLR2 Rev* GAG TCT AGA CTA GGA CTT TAT CGC AGC TCT C 
TLR10 Forw* AAC GTC GAC GAT TCA TAC ACC TGT GAA TAC C 
TLR10 Rev* GTT GTC GAC TTA TAG ACA ATC TGT TCT CAT CAG AGA G 
ENA-78 Promoter construct 
ENA-78 Forw* GCG GTA CCG AAT TCT CAG TAA GCG GAC TTA CCA AAG 
ENA-78 Rev* GAG GAT CCG GAG CAC TGT GG 
TLR10 chimeric constructs 
Forward TAC AAA GAC GAT GAC GAC AAG CTT GCG (pCMV-FLAG vector sequnce) 
TLR10 
ECD/TM Rev GGG CAG ATC CAA GTA GAT ACA GCA GAA GGC CAC AGCC AAC C 
TLR1  TIR 
Forw GGC CTT CTG CTG TAT CTA CTT GGA TCT GCC CTG GTA TCT C 
Reverse CAG GGT CAC AGG GAT GCC ACC C (pCMV-FLAG vector sequnce) 
TLR1 ECD/TM 
Rev GAT ACC AGG GCA GAT CCA AGT AGA TGC AGA GGG AGG TCA CAG  
TLR10 TIR 
Forw CCC TCT GCA TCT ACT TGG ATC TGC CCT GGT ATC TCA GGA TG 
TLR10 LRR6-
17 Forw* 
GGA AGC TAG CTC ATC TGC ATC TAA ATA CTG TCT TCT TAG GAT TCA 
GAA CTC TTC C 
TLR10 LRR6-
17 Rev* 
GGT TAA GCT TTC AGA TGA ATA GTC TCT TTA GGT ACA GTT TGG ATT 
TGG 
TLR-VLR constructs 
TLR1 ECD 
Forw TGT AGA TCT TCT GAA GAA AGT GAA TTT TTA GTT GAT AGG TC 
TLR1-VLR 
ECD Rev CACGCTCTTCAGCTGGTTGGAAGCAACATTGAGTTCTTGCAAAGC 
TLR1-VLR 
Forw 
CAAGAACTCAATGTTGCTTCCAACCAGCTGAAGAGCGTGCCTGATGGCA
TTTT 
TLR2 ECD 
Forw A GGT GGA TCC CTC TCC AAG GAA GAA TCC TCC AAT CAG G 
TLR2-VLR 
ECD Rev CACGCTCTTCAGCTGGTTCCTACTGATTTTCAATACTAGTAACATGGG 
TLR2-VLR 
Forw 
CTAGTATTGAAAATCAGTAGGAACCAGCTGAAGAGCGTGCCTGATGGCA
TTTT 
TLR10 ECD 
Forw AT AGA GGA TCC GAT GCT CCA GAG CTG CCA GAA G 
TLR10-VLR 
ECD Rev 
CACGCTCTTCAGCTGGTTGGATGCAATATTTAGTTCTCGTAAGGCCATCA
G 
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TLR10-VLR 
Forw 
CGAGAACTAAATATTGCATCCAACCAGCTGAAGAGCGTGCCTGATGGCA
TTTT 
VLR Rev TTGGCTAGCGGAGCCCCTTGGGACCAGAGTGGGGCAAATAATGGACCTCACTGGTTTTC 
TLR10 site-mutagenesis 
V311E Forw GGA GCA TGT ACA TTT CAG AGA GTT TTA CAT TCA ACA GGA TAA AAT C 
V311E Rev GAT TTT ATC CTG TTG AAT GTA AAA CTC TCT GAA ATG TAC ATG CTC C 
F312D Forw GGA GCA TGT ACA TTT CAG AGT GGA TTA CAT TCA ACA GGA TAA AAT C 
F312D Rev GAT TTT ATC CTG TTG AAT GTA ATC CAC TCT GAA ATG TAC ATG CTC C 
I314D Forw GGA GCA TGT ACA TTT CAG AGT GTT TTA CGA TCA ACA GGA TAA AAT C 
I314D Rev GAT TTT ATC CTG TTG ATC GTA AAA CAC TCT GAA ATG TAC ATG CTC C 
Q315L Forw GCA TGT ACA TTT CAG AGT GTT TTA CAT TCT ACA GGA TAA AAT CTA TTT GC 
Q315L Rev GCA AAT AGA TTT TAT CCT GTA GAA TGT AAA ACA CTC TGA AAT GTA CAT GC 
Q316K Forw CAT TTC AGA GTG TTT TAC ATT CAA AAG GAT AAA ATC TAT TTG CTT TTG ACC 
Q316K Rev GGT CAA AAG CAA ATA GAT TTT ATC CTT TTG AAT GTA AAA CAC TCT GAA ATG 
Y320N Forw GTT TTA CAT TCA ACA GGA TAA AAT CAA TTT GCT TTT GAC CAA AAT GGA C 
Y320N Rev GTC CAT TTT GGT CAA AAG CAA ATT GAT TTT ATC CTG TTG AAT GTA AAA C 
P339D Forw GAA AAC CTG ACA ATA TCA AAT GCA CAA ATG GAC CAC ATG CTT TTC CCG 
P339D Rev CGG GAA AAG CAT GTG GTC CAT TTG TGC ATT TGA TAT TGT CAG GTT TTC 
I359D Forw CCT ACG AAA TTC CAA TAT TTA AAT TTT GCC AAT AAT GAC TTA ACA GAC GAG TTG 
I359D Rev CAA CTC GTC TGT TAA GTC ATT ATT GGC AAA ATT TAA ATA TTG GAA TTT CGT AGG 
* indicates the engineered restriction sites. 
 
  
Table A.1 (continued) 
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